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ABSTRACT 
Ki67 is the most commonly used marker of proliferation in breast cancer. The general 
aim of the thesis was to investigate the prognostic role of Ki67 and its interplay with 
other prognostic factors in breast cancer cohorts.  
In Paper I, the prognostic value of Ki67 as analysed in metastasis biopsies (mKi67) 
and the change in Ki67 from primary tumour (pKi67) to corresponding first site of 
relapse was studied in patients diagnosed and treated for metastatic breast cancer 
(MBC) at Karolinska University Hospital (Stockholm, Sweden). A significantly longer 
median post-relapse overall survival (OS) was demonstrated for low-mKi67 (≤20%) 
compared with high-mKi67 (>20%) group (25 vs.17 months, p 0.01 by log-rank test). 
mKi67 was associated with OS regardless of pKi67. Ki67 varied from primary tumour 
to metastasis in a significant number of patients (p 0.01 by McNemar's test) and the 
change from high to low was correlated to better OS in comparison with stable Ki67 
levels.  
In paper II, the prognostic value in terms of post-relapse OS of breast cancer subtypes 
and genomic signatures as assessed in primary tumour tissue was investigated, beyond 
classical clinical and pathological prognostic determinants, in patients diagnosed and 
treated for MBC at Karolinska University Hospital. Immunohistochemistry-(IHC) and 
PAM50-based intrinsic subtypes showed a significant but not independent prognostic 
value after distant relapse. Moreover, low and medium-risk categories according to 
PAM50 risk of relapse score (ROR-S) were independently associated with longer 
post-relapse OS in comparison with the high-risk category. In contrast, the 21-gene 
Recurrence Score and the 70-gene signature were not independently prognostic of 
post-relapse survival. The PAM50-derived proliferation score also independently 
correlated with survival and the additional clinical information deriving from 
combining ROR-P (ROR-S weighted for the proliferation score) with the other 
prognosticators was also highly significant (p < 0.001).  
In paper III, the additional prognostic information deriving from the combination of 
genomic signatures and IHC markers, namely Ki67 alone or added to oestrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 
receptor (HER2) to generate IHC subtypes, compared with either classifier alone was 
investigated in two cohorts. Cohort 1 included patients with diagnosis of primary 
breast cancer from the Stockholm Breast Cancer Registry (SBCR) while cohort 2 was 
composed of women diagnosed with primary tumour in Uppsala county (Sweden). In 
cohort 1, 21-gene Recurrence Score and PAM50 added relevant prognostic 
information beyond Ki67/IHC subtypes. All the investigated genomic signatures 
provided additional prognostic information when combined with Ki67/IHC subtypes 
in the group of ER-positive/lymph node positive tumours while no signature reached 
the statistical significance when ER-negative tumours were studied. IHC subtypes, but 
not Ki67 alone, showed additional prognostic ability when combined with all genomic 
signatures except PAM50, in the overall cohort 1 and ER-negative subgroup, but not 
in ER-positive/lymph node negative and ER-positive/lymph node positive tumours. In 
 cohort 2, the findings were substantially comparable but the statistical significance 
reduced likely due to the smaller sample size. 
In Paper IV, the change in survival after local and loco-regional relapse of breast 
cancer over 34 years (1980-2014) was studied in a cohort of patients from the SBCR. 
Survival was compared between three cohorts according to years of relapse diagnosis: 
1980-1989; 1990-1999; 2000-2014.  In total, 1922 women were diagnosed with local 
and 776 with loco-regional relapse. In the group of the local recurrence, median post-
relapse event-free survival (EFS) and OS significantly improved over time, regardless 
of age. Conversely, age-related trends in survival were demonstrated in the group of 
women who experienced a loco-regional relapse. Relative survival was consistent with 
the observed EFS and OS. In addition, a decrease in mortality over time was 
demonstrated only in younger patients diagnosed with a loco-regional relapse in 2000-
2014 (EMR 0.48; 95% CIs 0.42-0.72), regardless of other prognostic factors. The 
outcome was unchanged when the analysis was restricted to the years 1980 through 
2009. 
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BACKGROUND                                                                                  
 
1.1 EPIDEMIOLOGY OF BREAST CANCER  
 
Breast cancer is the most common malignancy in women accounting for about 25% of all 
cancers worldwide. Overall, 1.670.000 new breast cancers were diagnosed in 2012 with 
slightly more cases identified in less developed (883.000) than in more developed (794.000) 
countries (of these, 362.000 in European Union). In the years 2008-2012, there were 
approximately 6.232.000 incident cases of breast cancers across the world, of whom 
1.444.000 in European Union. Incidence rates vary nearly four-fold with the lowest estimates 
of 27 per 100.000 women in Middle Africa and Eastern Asia to 90 per 100.000 women in 
Western Europe. 1 Figure 1 presents the age-standardized rates of breast cancer per 100.000 in 
the female population. Recently, a systematic analysis for the Global Burden of Disease Study 
reported a further increase in breast cancer incidence with a total of 2.400.000 new cases in 
2015. 2 
 
Figure 1.  Estimated age-standardized incidence rates of breast cancer per 100.000 women (GLOBOCAN 2012, 
IARC). 
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In 2012, breast cancer was estimated as the fifth cause of death from malignancy in the world 
leading to 522.000 deaths. After lung cancer, it represented the second most frequent cause of 
death due to malignancy in industrialized countries accounting for about 15.8% of all cancer 
deaths, while it ranks as the main cause of death (14.3%) among all cancers in less developed 
regions. In 2012, the mortality rates varied from 6 per 100.000 in Eastern Asia to 20 in 
Western Africa. The range in mortality between world regions is less pronounced than the 
range in incidence thanks to the favourable prognosis of breast cancer, especially in high-
incidence developed countries (Figure 2). 1 Recent estimates from the Global Burden of 
Disease Collaboration appointed breast tumour as the leading cause of cancer death in women 
in 2015. 2  
 
   
In Sweden, breast cancer is the most frequent form of cancer within the female population 
accounting for 30% of all cancers. 3 As Figure 3 illustrates, the age-standardized incidence 
has doubled since 1960, while mortality has declined by nearly 7% over time in the overall 
Swedish population. 4 
 
 
 
Figure 2.  Estimated age-standardized mortality rates of breast cancer per 100.000 women (GLOBOCAN 
2012, IARC). 
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Albeit more women died from lung and colon-rectal cancer in 2012 in the general population, 
breast cancer was the most common cause of cancer death among women aged 65 or younger. 
Overall, 10-year breast cancer survival has generally increased from 50% to approximately 
80% since the beginning of 1960, with a parallel improvement registered in all age groups. 
The 5-year survival, which is strictly dependent on the disease stage ranging from nearly 
100% for stage 0-1 to 20% for stage 4-breast cancer, has also improved from 60% to 90% 
since 1960. 3  
The combination of mammography screening and improved adjuvant therapies has led to a 
reduction in death rates for breast cancer in the United States by approximately 30% since 
1970s, although the net screening contribution remains controversial. 5 Besides stage, 
oestrogen receptor (ER) is the longest established prognostic and predictive factor in breast 
cancer. 6 Based upon this evidence, trends in mortality variations by screening and early 
Figure 3. Age-standardized incidence and mortality rates of breast cancer per 100.000 women (age 0-74 
years) in Sweden (NORDCAN 2014) 
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disease systemic treatment have been reinterpreted in a molecular context indicating greater 
absolute death rate declines in ER-positive (median 17 per 100.000 women, range=13-21) 
than ER-negative cancers (median 5 per 100.000 women, range=3-6) in the years 1975 trough 
2000, largely owing to the use of tamoxifen. In contrast, similar decrease in death rates was 
observed for ER-positive and ER-negative cases (median 16.7% vs. 14.0%, respectively), 
where no adjuvant treatment was assumed. Interestingly, among only screening-detected 
invasive tumours (thus excluding over-diagnoses) the overall 5-year survival probability was 
higher in ER-negative tumours (35.6% vs. 30.7%), mainly as an effect of the absolute higher 
survival gain obtained by diagnosis at an earlier stage in this tumour subgroup (25.6% vs. 
20.2%). 7 These data provide further support to the molecular and clinical heterogeneity of 
breast cancer 8,9 and motivate novel screening approaches that might more efficiently detect 
fast-growing tumours in high-risk population, ex. BRCA1-mutation carriers. 7  
Despite advances in systemic therapies, metastatic breast cancer is still treated with a 
palliative intention. In contrast to reports from population-based studies suggesting that 
survival for patients diagnosed with systemic disease between 1970 and 2000 has modestly 
improved over time in the United States 10-12, no general improvement was observed in the 
same years in a large cohort of women who received adjuvant systemic treatment within 11 
randomized trials. 13 An analysis from the Breast Cancer Registry in Stockholm (Sweden) 
revealed that age-related trends in survival exist and that prognosis is more favourable for 
women 60 years or younger diagnosed with a distant relapse after 2000 in comparison with 
previous time periods, presumably thanks to the availability of newer and more efficacious 
drugs. 14  
 
1.2 CLASSIFICATION OF BREAST CANCER 
 
Breast cancer is a heterogeneous disease comprising multiple entities with different 
histological and molecular features characterized by distinctive clinical behaviours and 
response to treatment. Thus, a central component of the treatment of breast cancer is the 
knowledge of its extent and biological properties. In clinical practice, categorization of 
tumours is a tool to guide or standardize treatment, planning for follow-up, selecting clinical 
trials and strengthening translational research. Great advances in refining breast cancer 
molecular classification and prognostication have characterized the last two decades. Here, a 
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traditional histo-pathologic classification of breast neoplasm is presented, along with more 
integrative biological and molecular characterization.  
 
1.2.1 MORPHOLOGICAL CLASSIFICATION 
 
Morphologically, breast cancer can be classified into clinically relevant subgroups based on 
histological types. 15 
“Histological type” refers to the growth pattern of the tumour. 16 At a cellular level, normal 
breast lobules comprise cells with regular, rounded nuclei organized in glands or tubule with a 
few proliferating cells. The tumour structure can range from stroma-enriched pattern with a 
glandular frame with minimal atypia, to highly atypical carcinoma cells growing as solid 
sheets or tumour characterized by a mixture of atypical cells with stroma, pre-invasive 
lesions, and normal breast tissue. 17 A traditional pathology-driven classification by the World 
Health Organization (WHO) identifies two common types of breast carcinoma: non-invasive 
(or in situ) and invasive breast carcinoma. Two major carcinomas in situ, which are both 
precursors of the invasive counterpart, have been identified: the ductal and the less common 
lobular carcinoma in situ. 18 Due to their distinct clinical behaviours, different treatment 
recommendations have been formulated. 19 Additionally, according to the most recent breast 
cancer staging systematized by the American Joint Committee on Cancer (AJCC) lobular 
carcinoma in situ is no longer considered cancer in situ but rather a benign entity and risk 
factor for cancer without metastatic potential. 20 The most common breast invasive 
carcinoma, accounting for the 70-75% of this morphological category, is the carcinoma of no 
special type (NST), previously defined as ductal carcinoma not otherwise specified (IDC-
NOS). 18 This is a diagnosis of exclusion and refers to those carcinomas that do not show 
sufficient characteristics to warrant their categorization in one of the special types. The 
special types account for about 25% of all breast cancers and comprise at least 17 distinct 
histological variants. 16,18 Among them, invasive lobular carcinoma is the most common and 
includes, besides the classical form, many other subclasses defined by peculiar 
morphological, clinical and biological features. 18 Due to relatively rare prevalence, lack of 
standardized diagnosis criteria and low inter-observer reproducibility, special types of 
carcinoma have not been systematically investigated in microarray-based gene expression 
studies and precise indications on tailored treatments have not been proposed, to date. 16 
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Finally, in addition to carcinomas, mesenchymal tumours (including sarcoma), which 
originate from the connective and fat tissue surrounding the breast gland, are described.  
 
1.2.2 IMMUNOHISTOCHEMICAL CLASSIFICATION 
 
Currently, four immunohistochemical biomarkers are used in routine clinical practice: ER, 
progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki67.  
 
1.2.2.1 Hormone receptors 
 
Overall, more than 75% of breast carcinomas express the hormone receptors ER and/or PR. 
The percentage of cancer cells stained for those biomarkers has valuable prognostic and 
predictive information. 21 ER is an intracellular protein mostly expressed in breast, 
endometrium, ovarian stroma and hypothalamus. PR is also an intracellular protein and its 
gene is transcriptionally activated by ER by binding to ER binding sites, so-called ERE, 
present upstream to PR gene. 22 The expression of PR, thus, correlates to that of ER, and, for 
this reason, the existence of ER-negative/PR-positive breast cancers is highly controversial. 
ER and PR are currently measured by immunohistochemistry (IHC), which replaced the 
ligand-binding assay in the US in the early to mid-90s. IHC, which uses a monoclonal 
antibody-based biochemical method to identify specific sequences on the receptor gene, faces 
limitations mainly related to inter-laboratory as well as inter-observer discrepancies. 17 In 
order to make ER and PR assessment more homogeneous, in 2010 the American Society of 
Clinical Oncology (ASCO) and the College of American Pathologists (CAP) set the new cut-
off to distinguish positive from negative cases at the clinically significant level of ≥1%. 21 In 
Sweden, where IHC definitely replaced the cytosol assay in 2003, a cut-off of 10% is 
currently recommended 23, and whether endocrine therapy should be administered when ER 
expression levels is comprised between 1% and 9% is still debated. A Swedish study, in 
which the IHC cut-off was set to ≥10%, demonstrated that, among ER-negative tumours, just 
a few falls in the 1-9% range and that no benefit was derived from tamoxifen given when ER 
was ≤10%. 24 
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1.2.2.2 Human epidermal growth factor receptor 2 
 
The clinical significance of HER2 in breast cancer has evolved from a marker of poor 
prognosis to a marker of response to treatment with therapies targeting the receptor. 25 HER2, 
also known as HER2/neu or ErbB-2, is a trans-membrane receptor member of the Epidermal 
Growth Factor (EGF) Receptor Tyrosine Kinase (RTK) family. It is encoded by the ERBB2 
gene located on the long arm of the chromosome 17 (17q21-q22). HER2, which normally 
regulates cell growth, differentiation and survival, is overexpressed in 15-20% of invasive 
breast cancers and correlates with more aggressive cancer features. 26,27 HER2 receptor, which 
has no high-affinity ligand, is activated for homodimerization or heretodimerization with 
other HER receptors and, possibly, for auto-cleavage of the extra-cellular domain. The 
binding to HER3 receptor generates a dimer of high-signalling potency. 25 HER2 content is 
routinely analysed either by HER2 protein quantity measurement by IHC or determining gene 
amplification by fluorescence in situ hybridization (FISH). Updated recommendations on 
HER2 testing have been published in 2013. 28   
 
1.2.2.3 Ki67 
 
Ungoverned cellular proliferation is a hallmark of cancer. 29 Ki67, currently the most 
commonly used biomarker of proliferation in routine clinical practice, is a non-histonic 
nuclear protein expressed at crescent levels during all the active phases of the cell cycle. 30 
Ki67 acts as surfactant by generating a steric and electrostatic charge barrier on the 
chromosomal periphery, which prevents chromosome collapse into a mass after nuclear 
envelope disassembly during cell division. In this manner, Ki67 enables the motility of 
chromosomes and their interaction with the mitotic spindle. 31  
Tumour proliferation rate is generally assessed as the number of cell nuclei positively stained 
for Ki67 antibody, among the whole number of scored malignant cells. Several monoclonal 
antibodies against the Ki67 antigen have been developed. The original antibody presented by 
Gerdes and coll. in 1983 was only for use in frozen tumour sections whereas more recent 
antibodies can be used on paraffin embedded specimens. Of those, Mib-1 is the antibody 
routinely employed. 32  
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The majority of the studies consistently appointed Ki67 as an independent prognostic factor of 
disease-free survival in early breast cancer. 33 Nonetheless, despite efforts put in the 
implementation of quality assurance schemes, the reproducibility of Ki67 measurements 
between laboratories, although improved, is still controversial and clinical useful thresholds 
for Ki67 categorization are not unanimously defined, to date. Given these (pre-) analytic 
caveats, an International Ki67 in Breast Cancer Working Group discouraged Ki67-driven 
clinical decisions. 34 
 
1.2.2.4 Immunohistochemical subtypes 
 
Based upon the abovementioned biomarkers, breast cancer has traditionally been classified 
into four IHC subtypes, which partially recapitulate the intrinsic subtyping defined by gene 
expression profiles (See chapter 1.2.3 hereunder) 8,9: Luminal A and B, HER2-positive and 
triple negative (TNBC) subtypes. Luminal A subgroup is characterized by high levels of 
hormone receptors and low levels of Ki67, while Luminal B tumours show higher 
proliferation rate and low hormone-receptor expression. 35 A 20% cut-off for PR has shown 
ability to improve the identification of good outcome Luminal A breast cancers. 36 HER2-
positive subtype is highly heterogeneous and comprises both clinically hormone receptor 
positive and negative tumours. Cancers overexpressing HER2 are generally highly 
proliferative and show low levels of luminal and basal gene clusters. 37 Finally, TNBCs are 
typically hormone receptor negative/HER2-negative and highly proliferative. An expanded 
immune-panel including cytokeratin 5/6 and the epidermal growth factor receptor (EGFR), 
provides a more refined and clinically relevant characterization of TNBC, on the top of ER, 
PR and HER2. 38 TNBC subtype is unanimously recognized as holding the worst prognosis 
and should be conceived as a biologically and clinically distinct entity. 39-41 In addition to that, 
breast cancer subtypes are also characterized by different response to systemic therapies. 
Indeed, HER2-positive and TNBC are more sensitive to chemotherapy than Luminal tumours, 
in particular Luminal A. 42  
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1.2.3 INTRINSIC SUBTYPES 
 
Almost two decades ago, hierarchical clustering based upon the unsupervised analysis of 9000 
differentially expressed “intrinsic” genes between tumour samples segregated breast 
carcinoma in two main clusters, mostly dominated by ER expression, and five sub-clusters, 
referred as ”intrinsic subtypes” (Figure 4A). 8,9 The subtypes were successively validated in 
several independent cohorts. 43-48 The ER-positive cluster is the most represented and can be 
further separated into two subtypes, Luminal A and B, identified by the expression of genes 
reminiscent of the luminal breast epithelial cells, such as ER, GATA3, XBP1, FOXA1 and 
low weight cytokeratin 8/18, among others. Luminal B is biologically characterized by higher 
expression of genes related to cell proliferation (i.e. MKI67 and AURKA) compared to the 
Luminal A subgroup, which has been shown to have higher expression levels of ER-activated 
genes (Figure 4C and F). 8,9,43,49,50 In contrast, basal-like breast cancers are distinguished by 
the expression of genes of the myoepithelial/basal epithelial cells (such as KRT5/6A, ID4, 
FOXC1) (Figure 4D). Basal-like tumours represent a unique molecular entity and are largely 
but not completely captured by TNBCs. 37,51  Indeed, this subgroup presents the highest 
intrinsic diversity depending on the complex genomic landscape. 9,40,41,52 TP53 is frequently 
mutated and a vast variety of copy number alterations (CNAs) as well as gene mutations have 
been described. 53 Additionally, basal-like subtype is associated with BRCA1 germline 
mutations. 43 In fact, the phenotypic features of basal-like breast cancers recapitulate those of 
tumours arising in BRCA1 germline mutated carriers and there is increasing evidence 
suggesting a dysfunctional BRCA1 pathway in sporadic basal-like tumours. 54 Similarly, 
HER2-enriched subtype, defined by the amplification of genes associated with HER2 
pathway and/or HER2 amplicon on 17q12 (i.e. GRB7), displays a high grade of internal 
diversity, including a number of subsets with distinctive ER, CNAs and mutational patterns. 
42,49,55-57 HER2-enriched tumours are highly proliferative and show lack of expression of 
genes within the luminal and basal cluster (Figure 4B). 37 Clinically, 70% of the tumours 
classified as HER2-enriched by gene expression profiles are also HER2-positive, as well as 
many HER2-amplified/ER-positive cancer are rather classified as Luminal B. 42,49 This 
incomplete overlap might be explained by similar functional events, such as the mutation of 
HER2 gene or components of the downstream pathways, which mimic HER2 amplification 
but are not translated into the HER2 overexpression. However, increasing evidence suggest 
that HER2-enriched intrinsic subtype may identify a subgroup within HER2-positive tumours 
more likely to achieve high response rate to dual HER2 blockade. 57-61 Together basal-like, 
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HER2-enriched breast tumours and Luminal B have a more aggressive behaviour compared to 
Luminal A subtype. 9 Lastly, a category showing gene expression features usually expressed 
by the adipose tissue and clustering with fibroadenoma and normal breast tissue, the so-called 
normal-breast like subtype has been identified (Figure 4E). However, the clinical relevance of 
this subtype is still unclear and many consider it as a mere artifact, likely attributable to a 
specimen contamination by normal tissue. 17,49,62 
 
 
 
Figure 4. Hierarchical clustering of 115 tumours and 7 non-malignant breast tissues using the “intrinsic” gene 
set. In the upper part of the figure: dendogram showing tumor clustering into 5 subgroups (A). In the lower part 
of the figure: gene clusters associated with the ERBB2 oncogene and other co-expressed genes (B); the luminal 
B subtype (C); the basal-like subtype (D); the normal breast-like group (E); the estrogen receptor (ESR1) highly 
expressed in luminal subtype A tumors (F) (Modified from Sorlie el al., PNAS 2003)  
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Recently, the US Food and Drug Administration approved the Prosigna test based on a 
reduced version of the original intrinsic subtyping, referred as PAM50 because it contains 50 
genes among those into the “intrinsic list”8 and is constructed according to the Prediction of 
Microarray algorithm (PAM). PAM50 classifies breast tumour in Luminal A and B, HER2-
enriched, basal-like and normal-like subtypes and provides a score that is predictive of risk of 
relapse (ROR) in ER-positive tumours. 49,63,64  
Less common intrinsic subtypes have been described, such as claudin-low and the molecular 
apocrine subtype. 65,66 The classical “intrinsic gene” sets 8,9,48 do not identify them and are, 
thus, not further discussed here. 
 
1.2.4 CORRELATION BETWEEN IMMUNOHISTOCHEMICAL AND MOLECULAR 
SUBTYPES 
 
Even though IHC and gene expression based intrinsic subtypes moderately correlate to each 
other, they are not synonymous. 67 Intrinsic subtypes are, in fact, represented in each IHC-
based subgroup 68 and their identification has demonstrated clinical value. 58 Indeed, HER2-
enriched subgroup includes approximately 35% of HER2-negative cancers as defined by IHC, 
and only 52% of the tumours are ER-negative /HER2-positive. A moderate inconsistence has 
also been demonstrated between TNBC IHC-surrogate and basal-like subtype. TNBC is a 
highly diverse group composed of many cancer subtypes among whom basal-like tumours 
predominate (~70% of the cases, when claudin-low are ignored). Within basal-like category, 
approximately 85% of the cases are classified as TNBC, whereas ER-positive as well as 
HER2-positive subtype is also significantly represented. Of interest, TNBCs and non-TNBCs 
within basal-like tumours show a nearly complete overlap in the pattern of expressed genes, 
which strengthen the notion of their unique biology. 51 Global gene expression analysis has 
revealed the presence of at least 7 subtypes among TNBCs with potential therapeutic 
implications. 69 
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1.2.5 PATTERNS OF GENE MUTATIONS IN BREAST CANCER IN RELATION TO 
INTRINSIC SUBTYPES 
 
Massive parallel DNA sequencing in breast cancer has identified a wide range of DNA 
mutations, such as base substitutions, small insertions, deletions, structural rearrangements as 
well as CNAs. The most frequently mutated genes are TP53, PIK3CA, MYC, CCND1, 
PTEN, FGFR1, GATA3, RB1, ERBB2, and MAP3KI. 70 Large-scale mutation data series 
have provided the evidence that distinct molecular subtypes have different repertoire of 
mutations, but no mutation or gene is subtype-specific (Figure 5). In the ATLAS study, 
genomic drivers were correlated to clinical and pathologic features. For instance, PIK3CA, 
GATA3, MAP3KI, KMT2C, CBFB were more significantly mutated (>5%) in ER-positive 
cancers. However, while the repertoire of genes mutated in Luminal greatly varies in 
comparison with basal-like tumours, there is no highly recurrent mutation or highly recurrent 
mutated gene that defines Luminal A or Luminal B (Figure 5). 71 Indeed, recurrently mutated 
genes in Luminal B tumours are, among the others, PIK3CA, GATA3, PTEN and TP53, 
recapitulating at high grade those mutated in Luminal A subtype. In contrast, luminal B has a 
greater genomic complexity, have more CNAs and higher number of mutations. 71 
Furthermore, TP53 is mutated in high-grade ER-positive and is the only significantly mutated 
gene (>10%) in basal-like cancer, whereas CDH1 and HER2 are rarely mutated in ER-
negative subtype. 71,72 Interestingly, from a mutational perspective, the basal-like subgroup 
forms a unique group distinct from other breast cancers but with similarities with ovarian 
cancer as well as squamous lung and head and neck cancers. 51,73 Moreover, the molecular 
heterogeneity of HER2 subtype is reflected at the gene mutational level. In general, HER2-
subtype has the highest nucleotide mutation rate but reduced list of recurrently mutated genes. 
Mutations typical of ER-negative, such as TP53, and of ER-positive cancers, namely PIK3CA 
and GATA3, are frequently found also in HER2-negative/ER-negative and HER2-
negative/ER-positive subgroups, respectively (Figure 5). 71,72 However, mutations in PIK3CA 
are less common in HER2-positive than HER2-negative/ER-positive and equally represented 
in HER2-positive/ER-positive and HER2-positive/ER-negative tumours, which has important 
clinical implications in terms of therapy resistance prediction in HER2-positive malignancies. 
74  
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1.3 PROGNOSTIC AND PREDICTIVE FACTORS 
 
1.3.1 INTRODUCTION 
 
By definition, a prognostic factor is a clinical or biologic characteristic that is objectively 
measurable and provides information on clinical outcome at diagnosis, independently of the 
treatment. In cancer, prognostic markers are usually indicators of growth, invasion and 
metastatic potential. A predictive factor is a clinical or biologic characteristic capable to 
provide information on the likelihood of response to a given therapy and may serve to identify 
subpopulations of patients with a higher probability to benefit from a certain treatment. Such 
markers can be represented by the treatment target or by modulators of the expression and/or 
function of the target. Some factors in breast cancer function both as prognostic and predictive 
markers (e.g. HER2). 75  
Several genetic and genomic biomarkers are emerging in breast cancer field, beyond the 
traditional clinical and pathological factors. However, markers need to demonstrate three 
characteristics in order to be recommended for use in clinical practice 76,77:  
Figure 5. Significantly mutated genes and correlations with molecular subtypes (Cancer Genome Atlas 
Network, Nature 2012) 
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1) Analytic validity: it refers to the marker ability to precisely measure the molecular 
event of interest and focuses on the technical aspects of the assay including accuracy, 
reproducibility, dependence of pre-analytic issues and reliability.  
2) Clinical validity: it assesses the strength of the association between assay result and 
clinical outcomes, such as recurrence-free survival and overall survival. It is the ability 
to accurately divide the population in two or more groups that differ biologically and 
clinically. Measuring strength of this association is of primary importance in order to 
later proceed to the assessment of clinical utility of the marker. There are several 
methods to quantify the association, such as receiver operator characteristic (ROC) 
curves, the area under the curve of ROC analysis, sensitivity and specificity, as well as 
several study designs, which mainly depends on the study sample size (resampling 
methods for smaller cohorts; identification of a “validation” and a “test” set for larger 
cohorts). Reporting of the results from studies evaluating new biomarkers should 
adhere to the Reporting Recommendations for Tumour Markers Prognostic Studies 
(REMARK). 78 
3) Clinical utility: a clinically useful biomarker is a marker that impacts clinical decision-
making and patient outcomes when compared with a clinical situation in which it is 
not used. Proven analytic and clinical validity do not imply clinical utility. This is the 
case, for instance, of a biomarker that does not show to be independent from 
predictors already in use in clinical practice, despite an outstanding clinical validity. 
High-quality data are required to prove the clinical utility of a biomarker. 
Retrospective analysis of prospectively collected material, ideally from randomized 
trials, is a time- and cost-effective strategy. 77,79 
Additionally, a good candidate marker should be feasible, reproducible, widely available, 
readily interpretable, and not consume tissue needed for other tests. 80 
 
1.3.2 EARLY STAGE DISEASE 
 
1.3.2.1 Prognostic factors 
 
Prognostic factors in early breast cancer can be grouped as follows: 
 
§ Clinical factors: age; race.  
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§ Pathologic factors: primary tumour size; axillary lymph nodes involvement; stage; 
tumour morphology; histologic grade; peritumoural lymph-vascular invasion; 
hormone receptors and HER2 overexpression. 
§ Markers of proliferation: Ki67 (addressed in more detail in a separate section) 
§ Genomic profiles: PAM50; 21-gene Recurrence Score (RS); 70-gene signature; 
EndoPredict; Genomic Grade Index (GGI); Breast Cancer Index (BCI) 
§ Emerging biomarkers: tumour infiltrating lymphocytes (TILs) 
 
Clinical factors 
Age Both younger and older age is associated with poorer prognosis. 81 Patients aged 35 years 
or younger at diagnosis have a worse absolute 5-year survival (74.7 vs. 83.8 to 88.3 percent 
for women aged 35 to 69 years), even after adjustment for tumour stage, histopathologic 
characteristics and given treatments, indicating an intrinsic aggressive biology. 82,83 Women 
>65 years diagnosed with breast cancer have an increased mortality mainly due to later stage 
at diagnosis, comorbidities and less aggressive therapies. 84-86 Notably, in HER2-positive 
tumours age is not a factor significantly associated with prognosis both in women untreated 
and in those receiving trastuzumab. 87 An analysis on approximately 17.500 patients revealed 
that women ≤40 years diagnosed with luminal A or B breast cancer, but not those with HER2-
positive tumours, had a higher risk of dying compared to older women. 88  
Race Breast malignancy in less common in black that in white women in the USA. However 
despite a general decrease in death rates from breast cancer, mortality in black women is still 
higher and racial disparities in breast cancer are likely to continue, at least for the next few 
years, given the increasing incidence rates among black women. 89 Racial disparities may be 
attributable in part to socio-economic factors (lower access to health care system and 
screening, delay in treatment start) and in part to higher frequency of biologically aggressive 
basal-like tumours among African American women. 90 Currently, there is no indication for a 
distinct systemic management of early breast cancer in this group. A nation-wide study of 
women followed between 1961 and 2007 in Sweden revealed that, although breast cancer 
incidence has increased over time, it is lower among immigrants (especially those from Asia 
and Latin-America) but not among immigrants’ daughters when compared to native Swedes. 
Globally, mortality has decreased both for native Swedes and immigrants, whereas 20% 
higher case fatality among immigrants diagnosed with breast cancer in the most recent years 
was described. Higher socio-economic level was associated to higher incidence and lower 
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mortality. These disparities highlight the importance of targeting interventions on those 
women who are less likely to participate in screening programs and to adhere to prescribed 
therapies. 91  
Pathologic factors 
Primary tumour size is defined as the largest diameter of the primary tumour. The 5-year 
survival decreases from 91% for cancer <2 cm to 63% for those >5 cm. 92 Tumour size 
correlates with the risk of developing metastases in axillary lymph nodes but the two factors 
are prognostically independent to each other. The correlation between tumour size and nodal 
involvement as well as risk of death is weaker in ER-negative tumours. 93 
Axillary lymph nodes involvement and number of metastatic lymph nodes is a strong and 
independent prognostic factor. 92 The 5-year survival rate for tumours localized to the breast 
vs. tumours that spread to the regional lymph nodes is 99% and 85%, respectively 94, 
independently of tumour size. 92 In addition, the presence of micro-metastasis (<2mm) in the 
examined axillary nodes is associated with worse prognosis in comparison with no metastasis 
whereas no difference in survival emerged between node negative patients and those with 
isolated tumour cells. 95,96 Occult metastases when retrospectively identified in lymph node 
initially judged free of metastasis have a negative impact on survival. 96,97 
Stage Combined primary tumour size (T), axillary lymph node status (N) and presence of 
distant metastasis (M) contribute to breast cancer staging according to the TNM system. 20 
TNM is finally combined to provide an overall stage including 5 levels (or stages), from 0 to 
IV with decreasing rates of survival at 5 years. 98 Interestingly, the last update of AJCC 
staging suggestes an integrated model combining the anatomical staging of breast tumour 
with the molecular biomarkers for a more refined prognostic classification that recognizes 
intrinsic tumour biology. The proposed bio-score need to be validated on larger independent 
cohorts.  
Tumour morphology Lobular carcinoma is associated to a lower risk of recurrence 
compared to ductal carcinoma in the first 6 years after diagnosis but confers a significantly 
higher risk after six years. 99 Tubular, papillary, mucinous, medullary and adenoid cystic 
carcinomas have a better prognosis while micro-papillary and metaplastic are associated with 
shorter survival. 75 
Histologic grade is a prognostic marker that allows risk stratification within a given tumour 
stage. 100 The most widely used grading system is the Nottingham histological grading, also 
called Elston and Ellis grading, and represents an evolution of the Bloom-Richardson Grade 
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system. It assesses the degree of tumour differentiation (tubule formation and nuclear 
pleomorphism) and proliferative activity (mitotic index) by giving a score to each of these 
features and then deriving a final score. Based on this final score, tumours are further divided 
in three groups, of whom group 1 corresponds to the well-differentiated cancers with the best 
prognosis and group 3 to the undifferentiated cancers with the least favourable outcome. 101,102 
The clinical importance of grade 2 tumours has been largely debated. The gene expression 
profile of grade 2 tumours, in fact, recapitulates features of grade 1 and grade 3 tumours 
rather than showing a specific genomic pattern. 103 Despite concerns related to the low inter-
observer reproducibility, histologic grade has been incorporated in validated prognostic 
algorithms such as the Nottingham Prognostic Index and Adjuvant!Online 104 and microarray-
based genomic signatures for grade have been developed. 50,103,105,106 The prognostic role of 
histologic grade has been demonstrated in the original report 101 and subsequently validated. 
107 Given concerns related to low inter-observer agreement and lack of a well-characterized 
clinical value for grade 2 tumours, histologic grade is not presently included in the revised 
TNM staging system, although it is contained in the previously discussed bio-score. 20 
Peritumoural lymph-vascular invasion Traditionally considered a poor prognostic factor 
108, particularly in higher-grade tumours, according to more recent evidences it is significantly 
associated to other prognostic factors and its clinical utility is to be determined. 109,110 
Hormone receptors The prognostic relevance of ER and PR has been a matter of debate for 
many years. Recently, an analysis on 4000 patients enrolled in four clinical trials with a 
follow-up of 24 years described that ER-positive tumours have a lower annual hazard of 
recurrence compared to ER-negative tumours during the first 5 years (9.9% vs. 11.5, p 0.01). 
Beyond 5 years, hazards in ER-positive cancers are higher and remain fairly stable after 10 
years from primary diagnosis, regardless lymph node status. 111 PR is a well-known 
prognostic factor of time to recurrence and overall survival 112-114 and adds prognostic value to 
the IHC definition of breast cancer subtypes refining the identification of good outcome 
Luminal A tumours. 36 Furthermore, PR was found prognostic of survival after relapse in a 
retrospective cohort. 115 
HER2 In the absence of systemic therapy, HER2 overexpression is associated with poorer 
prognosis regardless of the axillary lymph node involvement. 116-118 HER2 retains a negative 
prognostic effect even in tumours ≤1cm with negative lymph nodes. 119 
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Genomic profiles 
Gene expression-based assays provide prognostic information beyond classical clinical and 
pathological variables, namely hormone receptor and HER2 status, stage, and grade. 
Unsupervised analyses have identified signatures associated to biological features, such as ER 
signaling or proliferation that led to identification of molecular “intrinsic” subtypes. 
Supervised analyses allowed the development of signatures prognostic of survival. Figure 6 
presents a list of the genes used in the commercially available multigene assays.  
 
 
 
For most of these assays, clinical utility has been demonstrated.  Table 1 summarizes the main 
features of commercially available gene signatures and provides an overview of the studies 
used in order to train and validate these gene arrays.  
 
Figure 6. Genes comprised within the multigene assays: A) PAM50; B) 21-gene Recurrence 
Score; C) 70-gene signature; D) Breast Cancer Index; E) EndoPredict (Modified from Kwa 
M. et al, Nature Reviews Clinical Oncology 2017) 
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Gene array Genes 
(n)
Source Platform Training set Initial validation set Output data Clinical application
PAM50 55* FFPE/FF qRT-PCR/      
microarray
/ nCounter
189 ER+/-, LN +/- 
tumour samples 
and 29 non- 
malignant breast 
tumour tissue 
samples
786 ER+/- tumour 
samples from L+/- 
disease
Lumina A 
Luminal B   
HER2E           
Basal- like 
Normal - like                                                             
Risk of Relapse 
score (low-
medium-high)
Prognosis in post-
menopausal 
women with ER+, 
LN+/- disease of 
stage 1 or 2
21-gene signature 21 FFPE qRT-PCR    447 ER+/-, LN+/-
tumour samples 
from three 
randomized 
trials
Largely ER+/ LN- 
tumours in the 
tamoxifen arm of the 
NSABP B-14 trial 
(including samples 
from the training set)
Recurrence 
Score (low- 
intermediate- 
high)
Recurrence risk in 
patients with ER+, 
LN- tumours
70-gene signature 70 FFPE/FF Microarray 78 ER+/-, LN- 
tumours, <5 cm 
from patients  
aged <55 years
295 ER+/-, LN+/- 
tumours, <5 cm from 
patients <53 years of 
age (including 
samples from the 
training set)
Continuous 
variable (good- 
bad prognosis)
Distant relapse free 
survival prediction 
in ER+/-, LN- 
tumours
Breast Cancer Index 7 FFPE qRT-PCR    60 ER+ tumours 
samples from 
patients 
previously 
treated with 
tamoxifen
588 patients with ER+, 
LN- tumours enrolled 
in the Stockholm trial
Continuous 
variable (low-
intermediate- 
high)
Distant relapse free 
survival prediction 
in ER+/-, LN- 
tumours. 
Prediction of 
benefit from 
extended adjuvant 
therapyEndoPredict 11 FFPE qRT-PCR    964 ER+, LN+/- 
tumours from 
patients treated 
with tamoxifen
378 ER+/LN +/- 
tumours from the 
tamoxifen arm of the 
ABCSG-6 trial and 
1,324 patients from 
the ABCSG-8 trial
EPclin 
continuous score 
(low- high)
Risk of recurrence 
at 10- years in ER+, 
LN+/- tumours. 
Risk of recurrence 
after 5-10 years of 
endocrine therapy
Genomic Grade Index 97 FF Microarray 64 ER+ tumours 
of histological 
grade 1-3
125 ER+/- tumours; 
histological grade 1-3, 
LN- tumours
Continuous 
variable (low-
high)
Prognosis and risk 
stratification based 
on histological 
grade
*5 genes for expression normalization
Abbreviations: FFPE, formalin-fixed parrafin- embedded; FF, formalin-fixed; ER, estrogen receptor; LN, axillary lymph nodes; qRT-
PRC, quantitative reverse transcription polymerase chain reaction.  
 
 
 
PAM50, introduced in 2009 by Parker and coll., characterizes individual tumours by intrinsic 
subtypes using a set of 50 genes (Figure 6A). 49 PAM50 provides a continuous ROR-score 
(ROR-S), which ranges from 0 to 100 and stratify patients with ER-positive disease in low, 
medium and high-risk subgroups on the basis of the 10-year risk of recurrence. The test is 
performed on formalin-fixed, paraffin-embedded (FFPE) samples with high degree of analytic 
validity. 63 PAM50 was developed using microarray and quantitative reverse transcription 
polymerase chain reaction (RT-PCR) data from a set of approximately 190 ER-positive and 
negative/lymph node positive and negative prototypes 49 and validated in a set of over 700 
samples. 63 In this cohort ROR combined to tumour size (ROR-T) showed prognostic ability 
Table 1. Overview of the commercially available gene expression signatures in breast cancer  
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beyond classical clinicopathologic markers including Ki67, PR and grade. A ROR model 
weighted for 11 proliferation genes (ROR-P), among the overall 50 genes, further enhanced 
the prognostic value of ROR score. The clinical utility of PAM50 and ROR has been 
validated in several cohorts. 63,120-123 Using data from two separated trials, PAM50 and ROR 
added prognostic information to that derived by clinical factors. In an analysis in patients 
treated with adjuvant anastrazole or tamoxifen, ROR showed a continuous relationship with 
risk of distant recurrence at 10 years, regardless of nodal involvement. 121 The findings were 
confirmed in a cohort of post-menopausal women enrolled into the ABCSG-8 trial. 123 Two 
subsequent analyses in the same cohort revealed that PAM50 and ROR are also predictive of 
local recurrence 124 and accurately differentiate patients on the basis of the risk of relapse 
beyond 5 years from primary diagnosis. 125,126 Importantly, PAM50 may identify patients, 
within those who are diagnosed with HER2-postive tumours, who express genes of the basal-
like pattern and are less likely to respond to trastuzumab 127 as well as those who are classified 
as HER2-enriched and benefit the most from dual HER2-blockade. 58 Currently, the 
Nanostring’s technology used for quantification in the Prosigna assay has been validated 
using FFPE breast tumour samples across multiple laboratories 128 and has been approved in 
2013 for use in post-menopausal women with hormone receptor positive lymph node 
positive/negative disease.  
The 21-gene RS is among the earliest and best-validated prognostic assays in early breast 
cancer. Presently, there is strong evidence supporting the use of RS for recurrence prediction 
in ER-positive, HER2-negative, node negative cases and to guide decision regarding adjuvant 
chemotherapy. 129 Based upon 16 tumour-associated and 5 controls genes (Figure 6B), the 
signatures provide a continuous RS computed with mathematical algorithms. The score, 
which ranges from 0 to 100, categorizes patients into 3 risk categories, as follows: low-risk, 
RS <18; intermediate-risk, RS 18-30; high-risk, RS ≥31. 130 The 21-gene RS was developed 
by identifying the 250 most promising candidate genes in the original training set, which 
included 447 samples from patients enrolled in three separated trials, as described by Paik and 
coll. 130 A RT-PCR method was used in order to quantify the expression levels of the 
candidate genes. The higher expression of genes in the ER-pathway, GSTM1, BAG1 is 
associated with favourable prognosis and results in low RS, whereas expression of 
proliferation related genes, such as Ki67 and cyclin B1, genes within the HER2 and invasion 
pathway produce higher RS score. RS has been validated as prognostic tool to identify very 
low-risk patients among those with ER-positive, HER2-negative, node negative tumours, 
which could be safely spared from chemotherapy. 131 Presently, the RS lowest cut-off 
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supporting clinical decisions on chemotherapy remains unclear due to different proposed 
thresholds. Indeed, the most of the “prospective-retrospective” analyses appointed <18 as a 
cut-off to separate low and intermediate-risk cancers 130,132-134, while Sparano et al. in 
TAILORx study prospectively validated the ≤10 threshold. 131 The TAILORx study was 
designed to prospectively validate the 21-gene RS in a population of patients with ER-
positive, HER2-negative, node negative tumours for whom adjuvant chemotherapy was 
indicated based on clinicopathologic features (tumour size >1.1 cm or 0.6-1.0 cm but 
intermediate-high histologic grade). The first results of the TAILORx trial indicated that 
patients with RS ≤10, appointing a very low-risk of relapse, may forgo adjuvant 
chemotherapy and receive endocrine therapy alone. In fact, in this group risk of distant 
relapse was less than 1%, of any relapse was in the range of 2-5% and overall survival rate 
98% at 5-year follow-up. In an exploratory analysis following the publication of the 
TAILORx study, we retrospectively identified patients (n=908) in the Stockholm regional 
registry diagnosed during 2005-2006 with ER-positive, HER2-negative, lymph node negative 
tumours that were treated with adjuvant endocrine therapy alone. We found that Ki67 ≤10% 
identified patients whose outcome is in the same range as that in the population by Sparano et 
al., and might represent a surrogate to RS in identifying patients to be treated with adjuvant 
hormonal treatment alone. 135 Additionally, Plan B trial demonstrated that high-risk patients 
according to clinical factors but low-risk according to RS ≤11 and not receiving adjuvant 
chemotherapy had the same outcome as tumours classified as intermediate-risk cancers (RS 
12-25) treated with chemotherapy and better prognosis than high-risk cancers (RS>25) 
receiving chemotherapy. The trial also highlighted the need of integration of gene assay and 
clinicopathologic factors given a substantial discordance between each other. 136 Whether RS 
is of aid in the decision-making on adjuvant treatment in node positive tumours is matter of 
on-going debate. In fact, although there is evidence in favour of the use of RS in predicting 
benefit from adjuvant chemotherapy 137-139, especially in presence of limited nodal disease 136, 
data are not conclusive and a higher degree of caution in presence of node positive tumours is 
required in the light of the higher absolute risk of relapse. The results from the RxPonder trial 
will more exhaustively clarify on the topic. 140 Finally, the use of 21-gene RS signature in 
hormone receptor negative tumours is not supported. 129 
The 70-gene assay was the first multigene test approved by FDA in 2007. Initially developed 
by Agendia (Amsterdam, The Netherlands) based on Agilent microarray-based platform 
(Agilent Technologies, Santa Clara, CA) using unfixed fresh-frozen tissue, it has now been 
adapted and validated for use on FFPE tissue. 141,142 On the basis of a supervised DNA-
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analysis, the 70 genes comprised in this expression signature were selected among 25.000 
genes from a training set of 78 patients all aged <55, with no nodal involvement and not 
receiving systemic adjuvant treatment. 143 These genes are mainly related to proliferation, 
invasion and angiogenesis and are associated to tumour progression and metastasis (Figure 
6C). A mathematical formula allows separate patients into two risk groups according to the 
likelihood of developing distant metastasis at 5 years. The clinical validity of this signature 
has been demonstrated in several cohorts, some of them including tumours with lymph node 
metastasis. 144-150 The RASTER study was an observational study that provided the first 
prospective validation of 70-gene assay clinical utility. Patients who were classified as low-
risk according to the 70-gene signature and omitted chemotherapy had an excellent prognosis 
at 10-years, regardless the clinical-risk. 151 Recently, the MINDACT trial suggested that the 
70-gene signature may identify patients with low-risk of distant recurrence among those with 
high clinical risk. Risk assessment was made on the basis of Adjuvant!Online and the 70-gene 
assay. Women with discordant risk prediction were randomly assigned to adjuvant 
chemotherapy or endocrine therapy. Approximately 80% of the enrolled patients had negative 
axillary lymph nodes. In the discordant group, women with high clinical but low genomic risk 
who received chemotherapy had 95.9% rate of metastasis-free survival at 5 years vs. 94.7% 
for those treated with endocrine treatment alone.  However, the study was not powered to 
exclude a benefit from chemotherapy and did not demonstrate a clinical usefulness in 
demonstrating efficacy of chemotherapy in the small subset of women diagnosed with clinical 
low-risk/genomic high-risk tumours. 152 Based on these results, ASCO guidelines support the 
70-gene signature as a tool for decision on withholding chemotherapy in high-clinical/low-
genomic risk malignancies that are hormone-receptor positive, HER2-negative and have no or 
limited nodal disease. 153  
Breast Cancer Index (BCI) derives from the combination of two profiles, the HOXB13-to-
IL17BR expression ratio (H:I ratio) and the Molecular Grade Index (Figure 6D). Using 
genome-wide microarray analysis, risk of recurrence in ER-positive tumours treated with 
tamoxifen was associated with the differential expression of 3 genes: the anti-apoptotic 
homeobox B13 (HOXB13, overexpressed in recurrent cancer treated with tamoxifen), and 
interleukin 17B receptor (IL17BR) and EST AI240933 (both overexpressed in non-recurrent 
cancers treated with tamoxifen). The H:I ratio correlated with clinical outcome, disregarding 
other established clinical prognostic factors. 154 The Molecular Grade Index evaluates the 
expression of 5 gene related to histological grade and tumour progression (Figure 6D). The 
combination of H:I ratio and Molecular Grade Index has more predictive value than the two 
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of them separately. 155 An analysis on 588 patients from the Stockholm trial, which compared 
the efficacy of tamoxifen vs. placebo, demonstrated the prognostic utility of H:I ratio and 
Molecular Grade Index. A BCI continuous score was derived and patients separated in 3 risk-
subgroups accordingly. Overall >50% were assigned to the low-risk group and <3% of them 
experienced a relapsed over 10 years. 156 BCI might predict endocrine responsiveness and 
identify patients more likely to benefit from extended adjuvant endocrine treatment. 157-159 
EndoPredict Based upon the expression of 8 cancer-related genes and 3 reference genes 
quantified by RT-PCR (Figure 6E), EndoPredict was initially validated in two trials (ABCSG-
6 and ABCSG-8), which demonstrated that this assay has independent value regardless 
classical prognostic factors. The gene signatures combined with tumour size and nodal status 
provides a risk score, EPclin, that stratifies patients into two categories on the basis on the 
recurrence risk at 10-years. 160 EndoPredict showed ability in identifying very low-risk 
tumours among those that are ER-positive and HER2-negative and is predictive of late 
recurrence. 161 Interestingly, EPclin identifies a subset of patients with very low risk of 
recurrence after 5-10 years of endocrine therapy and those who might be spared from 
extended adjuvant endocrine therapy. 161 The test performed in FFPE samples from core 
biopsies or surgical specimens produces reproducible and accurate results. 162,163 In the 
GEICAM 9906 trial, EndoPredict was able to independently predict the risk of relapse in low- 
and high-risk categories according to EPclin but did not demonstrate ability to predict the 
benefit deriving from adding paclitaxel to antracyclines. 164 Furthermore, EndoPredict and 
EPclin were highly prognostic of recurrence after endocrine therapy. EPclin was more 
prognostic than RS and this is in part, but not entirely, attributable to the fact that EPclin 
integrates molecular and clinical information from tumour size and nodal status. 165  
Genomic grade index (GGI) refers to a list of 97 genes that showed ability in distinguishing 
histological grade 1 from histological grade 3. 103,166 While in the initial report it was 
described that GGI reclassified grade 2 tumours improving the prognostic value of tumour 
grade 103, in later validation cohorts of untreated or tamoxifen-treated patients GGI was found 
to perform independently and equally well as RS as a prognostic marker 166, and to 
outperform histological grade and proliferation biomarker including Ki67. 167 However, grade 
2 tumours may be also accurately separated in risk categories by the cost-effective Ki67 168 
and, thus, further studies are required to prove the clinical utility of GGI. High expression 
levels of the genes within the GGI assay are strongly associated to high histological grade and 
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ER-negative status as well as to higher response rate to neoadjuvant chemotherapy but also to 
poorer prognosis after systemic chemotherapy. 169 
 
Emerging biomarkers 
Tumour infiltrating lymphocytes (TILs) Level 1b evidence suggests that TILs are 
prognostic in the context of adjuvant chemotherapy in TNBCs 170,171 but cannot be used for 
withholding chemotherapy. The analytic validity of TILs has been matter of debate due to low 
inter-observer reproducibility and the lack of an established clinically relevant cut-off. 170 
However, reproducibility of TILs assessment appears feasible and recommendations have 
been published in order to strengthen the clinical relevance of this immunologic biomarker. 
172,173 
 
1.3.2.2 Predictive factors 
 
Predictive factors enable treatment tailoring by providing tools for the identification of 
subjects with higher or lower likelihood to respond to a certain treatment. In this way an 
enhancement in response to treatment may be achieved and non-responsive patients may be 
spared from unnecessary therapies. The results of a metanalysis of over 100.000 patients 
included in 123 trials revealed that benefit from adjuvant chemotherapy is independent of age, 
ER status, grade, tumour size, nodal involvement and adjuvant tamoxifen. 174  
The only well-established predictive markers in early breast cancer are ER and HER2.  
ER The predictive role of ER has been extensively described in a metanalysis of over 20.000 
patients from 20 trials of adjuvant tamoxifen vs. no tamoxifen. In ER-positive tumours, 
tamoxifen was related to 39% and 30% decrease in the risk of recurrence and death at 15 
years, respectively. The results were independent of PR, age, nodal status and use of 
chemotherapy. By contrast, tamoxifen did not affect survival in patients with ER-negative 
disease. PR-positive tumours have a better prognosis when treated with tamoxifen. However, 
the expression of PR is dependent on ER and the predictive role of PR is thus unclear, 
especially when ER status is known. 175  
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HER2 is a predictive factor of response to HER2-targeted therapies and the benefit from 
trastuzumab in HER2-positive tumours has been well described both in the early 176-178  and in 
the advanced setting. 179-181  
 
In addition to these findings, some evidence of the predictive role of genomic signatures and 
Ki67 (see section 1.4 Markers of proliferation) is available. 
Genomic profiles may predict benefit from chemotherapy but cannot guide the choice of 
which type of cytotoxic drug should de administered. These findings have been discussed in 
the previous section. Emerging evidence from a phase II neoadjuvant trial revealed that a 
PAM50-based chemo-endocrine score predict response to chemotherapy in hormone receptor-
positive cancers. 182  
 
1.3.3 ADVANCED BREAST CANCER 
 
Metastatic breast cancer (MBC) is treated with palliative intention. Median overall survival in 
metastatic breast cancer approximates two years but can range from few months to many 
years. 14 The identification of prognostic factors of survival and predictive markers of 
response to therapy in this setting may contribute to a deeper understanding of the large 
variability in clinical outcome and aid the selection of more specific treatments.  
 
1.3.3.1 Prognostic factors 
 
Relapse free interval Patients who experienced a disease recurrence ≤2 years from primary 
diagnosis have a poorer prognosis after relapse in terms of time to relapse and overall 
survival. 14,183-185 
Age The effect of age on survival after recurrence in not clearly established. However, older 
age at the diagnosis of MBC might be prognostic of poorer survival 14 likely due to 
comorbidities, poorer performance status and less intensive anti-cancer treatment. 85 
Site of metastasis Chest-wall, skeletal and lymph node metastases are associated to a better 
post-relapse prognosis in comparison with visceral metastases. 14,183,184,186 
  26  
Adjuvant systemic treatment Disseminated use of adjuvant systemic therapies may be 
associated with worse survival after relapse, likely due to the selection of cellular clones with 
more aggressive features and resistance to treatment. 14  
Hormone receptor and HER2-status Hormone receptor positive primary breast cancers 
have a longer survival in the advanced setting. Tumours overexpressing both ER and PR have 
a better prognosis than those expressing either ER or PR. 187 HER2-positive tumours in pre-
trastuzumab era, and TNBCs have poorer prognosis. 185,188,189 When clinically feasible, re-
assessment of hormone receptor status and HER2 should be performed at least once in 
metastatic setting (level of evidence 1b, see paragraph 1.6 for a detailed discussion). 190,191 
Change in ER status from positive to negative in primary tumour tissue and metastasis has 
been associated to higher risk of death compared with stable ER status. 192 The discordance in 
HER2 status was also related to shorter post–relapse survival. 193,194 
 
Genomic profiles Early evidence suggests that PAM50 and the 21-gene RS assay may be 
useful for prognostication in MBC. 
Intrinsic subtypes have prognostic relevance in the advanced setting. A retrospective analysis 
from the Swedish multicentre randomized TEX study, in which 111 patients had a biopsy 
from loco-regional or distant relapse, described a shorter survival for basal-like and HER2-
enriched subtypes when compared with Luminal A. 195 Similarly, the Luminal B, basal-like 
and HER2-enriched tumours, as assessed from primary tumour or metastasis tissue, were 
associated with worse progression-free survival and overall survival in post-menopausal 
women treated with letrozole with or without lapatinib as first line treatment for MBC. 196 
Moreover, the 21-gene RS was found prognostic of progression-free survival and overall 
survival in a prospective registry study on de novo stage IV breast cancer. 197  
 
In order to define the prognostic role of IHC markers and gene expression signatures of the 
primary tumour in MBC, we performed a population-based analysis and compared the 
prognostic performance in term of post-relapse survival of different prognosticators in a 
cohort of women diagnosed with systemic disease and for whom tissue from primary tumour 
was available for IHC and RNA analysis. (Paper II: Falato C et al., Mol Oncol 2015). 
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1.3.3.2 Predictive factors 
 
Hormone receptor and HER2 status Overall, 14-32% and 10% discordance rate in hormone 
receptors and HER2, respectively, between primary tumour and corresponding metastasis has 
been estimated. 192,194 Beyond a proved prognostic role, the new expression pattern of ER, PR 
and HER2 may be of predictive value and according to expert opinions treatment should be 
guided by the phenotype of the metastasis rather than that of the primary tumour. 190  
Genomic profiles Retrospective evidence from a prospective trial suggested a predictive role 
for HER2-enriched subtype in ER-positive/HER2-positive tumours treated with lapatinib. 196 
Prospective evaluation of the findings is needed.  
 
Emerging biomarkers  
Androgen receptor TNBC is a highly heterogeneous entity that comprises multiple 
molecular subtypes and oncogenic drivers. Among these, the Luminal Androgen Receptor 
(AR) subtype, which well recapitulates the non-basal group within TNBCs, may be driven by 
AR-signalling and appear to have a more indolent behavior. 69,198 Enzalutamide, a potent 
inhibitor of AR approved for the treatment of prostate cancer, has been tested in a single arm 
phase II trial leading to an improvement in terms of progression free survival and overall 
survival, especially in AR-positive tumours by IHC. 199 However, phase III trials testing 
enzalutamide in breast cancer have been put on hold since enzalutamide development in 
breast cancer has been suspended.  
Germline BRCA mutations Among patients with HER2-negative metastatic breast cancer, a 
germline BRCA mutation may predict benefit from olaparib, a PARP-inhibitor, as compared 
with standard chemotherapy. 200 Interestingly, the benefit from olaparib was superior in 
TNBCs suggesting that the combination of two or more biomarkers can enhance the 
identification of the best target population. Moreover, evidence suggests that platinum agents 
are particularly active in TNBCs with germline BRCA 1/2 mutation. 201,202 
PI3K-AKT-mTOR pathway PIK3CA gene is mutated is one third of breast cancers and the 
most of the mutations are activating. 71 The efficacy of buparlisib, a pan-PI3K inhibitor, in 
combination with fulvestrant, a selective ER degrader, has been demonstrated in advanced 
breast cancer but not further investigated due to unacceptable toxicity. 203 PI3Kα inhibitors, 
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alpelisib and taselisib, combined with fulvestrant, have shown clinical activity, especially in 
PI3K-mutant tumours, and better tolerability than buparlisib in previous phase I and II trials 
204,205, and are now under investigation in Phase III trials. 206,207  
Estrogen-receptor 1 (ESR1) Pre-clinical and clinical evidence suggests that mutations of 
ESR1 gene promote ligand-independent activation of ERα in breast cancer conferring 
resistance to current anti-hormonal agents that cause oestradiol deprivation, namely aromatase 
inhibitors, but not to fulvestrant. The mutation, which is very rare in primary tumours but 
mutated in approximately one third of patients treated with an aromatase inhibitor, is 
associated with a more aggressive phenotype. Besides metastatic tumours tissue, ESR1 
mutation can be detected in plasma through circulating-tumour DNA-sequencing. 208-210 
Furthermore, retrospective analysis showed that ERS1-mutation is polyclonal and may be also 
found in cellular clones before treatment with aromatase inhibitors, indicating its potential use 
as a predictive factor for selection of hormonal therapies. 211-213  
Somatic mutations in HER2 TK-domain Prevalently activating, mutations of the HER2 
TK-domain are heterogeneous and particularly frequent in invasive lobular carcinomas. These 
mutations are associated with poor survival in HER2-negative breast tumours 214,215 and might 
represent a target for irreversible TK inhibitors, such as neratinib. 216,217 Studies specifically 
investigating how distinct mutations in HER2 TK-domain may predict response to therapy are 
needed in order to account for the high heterogeneity in the mutation pattern.  
 
1.3.4 LOCO-REGIONALLY RECURRENT BREAST CANCER 
 
Isolated local recurrence, referred as reappearance of cancer in the ipsilateral preserved breast 
or chest-wall after mastectomy, and loco-regional recurrence involving also ipsilateral 
regional lymph nodes (more frequently axillary and supraclavicular but also infraclavicular 
and/or internal mammary), is a negative prognostic factor, leading to a higher risk of distant 
relapse and poorer overall survival. 218,219 Overall, a multidisciplinary therapeutic approach of 
the loco-regional disease is recommended and has been related to a better post-relapse 
outcome. 220 After primary breast conserving surgery and radiotherapy, mastectomy is the 
standard surgical approach in case of isolated local relapse and may provide long-term 
survival. 221,222 Although similar prognosis has been described in case of loco-regional tumour 
reappearance after breast-conserving surgery and after mastectomy 223, post-mastectomy 
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recurrences tend to occur earlier and more often involve regional lymph nodes. These factors 
are both recognized as negative prognostic factors of post-relapse survival. 223-225 
 
1.3.4.1 Prognostic factors 
 
Regardless of the type of primary surgery, established prognostic factors after a loco-regional 
reappearance of breast cancer are: 
§ Invasive disease Invasive local recurrence is associated with a higher likelihood of 
developing a second local relapse and/or distant relapse as well as poorer post-relapse 
survival compared to a non-invasive relapse. 226,227 
§ Skin involvement A recurrence involving skin is associated with a worse post-relapse 
prognosis in comparison with a recurrence not including skin. 228 
§ Extensive local recurrence A local recurrence discovered by physical examination, 
and thus more extended, has a worse outcome in comparison with a recurrence 
diagnosed by mammography alone. 229 
§ Disease free interval Patients who experience a loco-regional relapse within 2 years 
from primary surgery have a poorer 5-year overall survival compared with those who 
recurre more than 2 years after the primary diagnosis. 218 
§ Age Younger age at primary diagnosis (≤35 year) was associated with poorer 
outcome. 230  
§ Larger primary tumour size, axillary lymph node positive status, ER-negative 
primary tumour, adjuvant chemotherapy are related to shorter post-relapse 
survival. 218,219,231,232 
 
1.3.4.2 Predictive factors 
 
There are no specific predictive factors to guide treatment after curative surgery of a local 
recurrence of breast cancer or after occurrence of a loco-regional recurrence. All ER-positive 
tumours should receive post-operative endocrine treatment 233, while greater benefit from 
chemotherapy has been demonstrated for ER-negative in comparison with ER-positive 
tumours according to a single randomized trial. 234 All HER2-positive tumours should receive 
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HER2-targeted therapies. The reassessment of hormone receptor and HER2 is strongly 
endorsed and the systemic therapeutic approach should be guided by the pathologic 
characteristic of the recurrence. 234 However, recommendations on a standardized therapeutic 
approach after surgery for an isolated local recurrence are presently still awaited.  
 
Survival after isolated local recurrence or loco-regional recurrence of breast cancer and how 
prognostic factors modulate prognosis has been matter of intense research. Several 
retrospective analyses from prospective trials have been published but information from 
population-based cohorts is scarce. . In Paper IV we explored how prognosis after loco-
regionally relapsed disease has evolved over the past three decades at the population level 
and whether trends in survival exist. (Paper IV: Falato C et al., manuscript) 
 
1.4 MARKERS OF PROLIFERATION 
 
Proliferation rate in breast cancer can be assessed by several methods, including mitotic 
counts, S-phase fraction by flow-cytometry, and IHC using monoclonal antibodies direct 
against antigens expressed in proliferating cells, such as cyclin A and Ki67. The most 
commonly used method to determine the rate of proliferative breast cancer cells is to evaluate 
the percentage of nuclei stained with the monoclonal murine antibody Mib-1, which detects 
the protein Ki67 with higher sensitivity than other comparable antibodies in FFPE samples. 32 
Many studies demonstrated a strong correlation between Ki67 and other well-known 
proliferation markers. 235,236 
 
1.4.1 KI67  
 
The prognostic value of Ki67 has been extensively investigated. 33 Despite inconsistencies in 
assessment methods and cut-points, two large meta-analyses consistently recognized Ki67 as 
a prognostic factor in early breast cancer, regardless of axillary lymph node status. 237,238 
However, retrospective nature of the majority of the studies exploring Ki67, variability in 
used antibodies, techniques and scoring protocols prevent a harmonious data interpretation. 
More recently, a retrospective analysis of clinical trials with centralized assessment of Ki67 
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described an independent value of Ki67 as a prognostic marker of disease-free survival, while 
only 1 out of 5 trials confirmed an independent association with overall survival. 33  
An IHC4 surrogate composed by centrally assessed ER, PR, HER2 and Ki67, which are 
combined in a weighted equation used to derive a IHC4 score, has been proposed as a cost-
effective alternative to PAM50. 239 Some studies have showed good performance of IHC4 in 
separating Luminal A and B 35 as well as equivalence with RS in survival prognostication 239, 
while other studies reported worse results for IHC4 in comparison with PAM50. 63 At present, 
ASCO and IMPAKT working group do not recommend Ki67 and IHC4 to assess prognosis in 
breast cancer. 129,240 
Ki67 as a predictive factor in the adjuvant and neo-adjuvant setting is more controversial with 
conflicting results from different studies. Indeed, some analyses showed that Ki67 could be 
predictive of benefit from taxanes 241,242 whereas other studies revealed that Ki67 might 
predict response to chemotherapy but not specifically to taxanes. 243 In addition, Ki67 was not 
predictive of response either to anthracyclines vs. first generation chemotherapy 244 or first 
generation chemotherapy plus endocrine therapy vs. endocrine therapy alone. 245 However, 
Ki67 was significantly associated to benefit from earlier treatment with aromatase inhibitors 
compared to their delayed administration after 2-3 years of tamoxifen. 246 In the neoadjuvant 
setting, no evidence indicating an association between pre-treatment Ki67 and response to 
treatment emerged from clinical trials testing chemotherapy, endocrine therapy or their 
combination. 33 Change in Ki67 during neoadjuvant endocrine treatment generated greater 
interest for its potential use as a marker of therapy benefit. In particular, early change in Ki67 
after two weeks of hormonal treatment has been demonstrated to precede and significantly 
correlate with clinical and pathological response and to predict long-term outcome. 247-249 Of 
interest, change in Ki67 levels was also shown during neoadjuvant therapy with everolimus 
and letrozole vs. placebo and letrozole, indicating anti-proliferative effect of everolimus. 250  
In the metastatic setting, high Ki67 from primary tumour tissue or locally recurrent tumours 
was associated to shorter post-relapse survival and to response to first line treatment with 
aromatase inhibitors. 251,252 
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1.4.1.1 Cut-off value of Ki67 for clinical use 
 
Ki67 is a continuous variable expressed as the percentage of positively stained cell nuclei 
within the scored area. Ki67 follows a lognormal distribution and the log-transformed value 
for Ki67 should be used for statistical purposes. 253 Many methods have been used to derive 
the best cut-off(s) for Ki67 categorization. 254 Although most of the studies recognized the 
prognostic value of Ki67, the comparability between them is low due to several limitations 
such as the wide range of the used cut-points. 235 Interestingly, in a prospective cohort Ki67 
has been found prognostic over a wide range of cut-points suggesting the data-derived cut-
point optimization (i.e. based on ROC curves, minimum sensitivity or specificity, significance 
of correlation with survival variables by log-rank test) may be suboptimal. 255 Recently, a 
panel of experts has recommended the use of Ki67 at very low (<10%) or very high >25% 
cut-off for prognostication purposes, in combination with other established prognostic 
determinants in breast cancer. 256  
 
Whilst the clinical validity of Ki67 as a prognostic marker in early breast cancer has been 
widely demonstrated and the instability of hormone receptors and HER2 expression between 
paired primary tumour and metastasis well recognized, the prognostic implications of Ki67 in 
the metastatic setting as well as the pattern of variation in Ki67 index during disease 
progression is not well characterized. In Paper I we sought to address the prognostic role of 
Ki67 as assessed in metastatic tissue and the clinical relevance of its change during 
metastatic progression. (Paper I: Falato C et al., Breast Cancer Res Treat 2014) 
 
1.5 IDENTIFICATION OF LOW-RISK CANCERS 
 
In the era of precision medicine to guide therapy decisions, a clinically relevant question is 
the identification, based on histopathological surrogates, of very low-risk primary cancers that 
could be safely spared from chemotherapy in the adjuvant setting. Very low-risk tumours 
have been identified exclusively in the Luminal A category by gene expression profiles 49,257 
and have shown to be relatively resistant to chemotherapy. 42 Notably, the most of the gene 
expression signatures concordantly identify a subset of Luminal A tumours with negative 
axillary lymph nodes, which could safely receive adjuvant endocrine therapy alone. 258 
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Biologically, the most distinguishing features between luminal A and B subtypes is the higher 
expression of proliferation-related genes in the latter. 35,63 Luminal B, that accounts for about 
20% of all Luminal tumours, have also higher RS as assessed by the 21-gene assay and poor 
70-gene prognostic signatures. 257 In a pivotal analysis, we have demonstrated that a threshold 
of 10% for Ki67 performs as good as the 21-gene RS signature in appointing very low-risk 
tumours within the ER-positive/HER2-negative/axillary lymph node negative cancers treated 
with adjuvant endocrine therapy alone.135 Moreover, PAM50 ROR has been shown to provide 
more information, beyond clinical prognostic factors, than RS but at least as much 
information as the standardized IHC surrogate (IHC4), using 14% as a cut-off for Ki67.121 
Nonetheless, the optimal Ki67 cut-point is presently still widely debated due to contrasting 
evidence in favor 35,259 or against the 14% threshold. 260 We described that Ki67, at different 
cut-points, and gene signatures do not harmoniously stratify patients in good or poor 
prognosis subgroups. 261 Thus, given the extreme biologic heterogeneity of luminal B tumours 
and the controversial reproducibility of the IHC biomarkers, especially for Ki67, the clinical 
issue of the identification of a strong histopathological surrogate to PAM50 in the 
characterization of Luminal A and Luminal B tumours remains to be solved.   
 
Based on this evidence, we explored whether IHC biomarkers and gene expression profiles 
might improve long-term prognostication when combined to each other rather than when 
used separately. The findings of our study are detailed in the section “Results” (Paper III: 
Lundberg A et al., CCR 2017).  
 
1.6 PHENOTYPIC AND GENOMIC HETEROGENEITY BETWEEN PRIMARY TUMOUR 
AND METASTASIS 
  
Two prospective trials and a numbers of retrospective analyses showed that ER, PR and 
HER2 are discordant across primary tumour and metastasis in a consistent proportion of 
patients. 192,194,262-264 Change from ER-positive to ER-negative as well as discordance in 
HER2 status in primary tumour and corresponding metastasis has been associated to a worse 
post-relapse prognosis as compared with stable receptor levels. 192-194 Moreover, results from 
prospective trials revealed that the change in biomarker expression during tumour progression 
led to a change in disease management in 1 every seven patients undergoing a relapse biopsy. 
  34  
265 More recently, the instability in molecular subtypes has been studied and a wide range in 
the rate of subtype conversion has been demonstrated, from 0% for basal-like tumours to 55% 
for Luminal A tumours. 266 Luminal A tumours tend to turn into Luminal B and, less 
frequently, into HER2-enriched subtypes reflecting tumour evolution and acquisition of 
oestrogen independence. Of interest, compared to primary tumours, metastases appear to be 
more enriched in proliferation and migration-related genes while depletion of luminal-related 
genes has been described in metastasis compared to matched primary tumours. 266  
The discrepancy in receptor pattern between primary tumour and relapse can be attributed to 
several factors and, although technical artefacts may account among them 267, a biological 
basis is present in many cases. Traditionally, primary breast cancers exhibit high intra-tumour 
heterogeneity with varying metastatic potential. 268 Cancer biology, in particular its intrinsic 
genomic instability, selective pressure by adjuvant therapy driving to the selection of resistant 
and more aggressive cellular clones and undetected small cellular sub-clones at the initial 
diagnosis are among the hypothesized mechanisms potentially generating alterations in 
tumour phenotype during disease progression. 268-271 Recent studies on next generation 
sequencing shed new light on the heterogeneity between primary tumour and metastasis and 
reinforced the hypothesis of a clonal genomic evolution at the bottom of the inconsistency in 
receptor expression pattern. Indeed, while initial studies identified very few differences 
between primary tumours and their metastatic deposit from a mutational perspective 272-274, 
higher degree of heterogeneity has later emerged with a more comprehensive genomic 
characterization. Primary tumour and metastasis are known to share mutations prevalently in 
frequently mutated genes, such as mutations in TP53, PIK3CA, GATA3, among others. 
However, in many distant relapses driver mutations private to metastasis have been found. On 
average, metastases contain an additional 63% mutational load compared to the primary 
tumour. Driver mutations acquired late encompass a wider range of cancer genes, are more 
likely the result of selection pressure from previous treatments and may more closely reflect 
metastatic environment and immune response. 275-278 Prototypical example of standard 
treatment pressure is represented by the mutation of ESR1 gene in metastasis of patients 
previously treated with an aromatase inhibitor. 275 Potential therapeutic implications deriving 
from this mutation have been discussed above.  
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AIM OF THE THESIS 
 
The general aim of the thesis was to gain insights into the prognostic role of tumour 
proliferation and its interplay with other prognostic factors in breast cancer. 
 
More specifically, the studies included in the thesis investigated: 
 
-The prognostic role in terms of post-relapse overall survival of Ki67 as assessed in the first 
site of distant metastasis. Whether Ki67 rate changed from primary tumour and matched 
metastasis with an impact on survival was also investigated (Paper I). 
 
-The prognostic value after diagnosis of systemic disease of IHC-and gene expression-based 
subtypes as well as genomic profiles from the primary tumour with a focus on the PAM50 
proliferation signature, beyond classical clinical and pathological prognostic determinants in 
breast cancer (Paper II). 
 
-Whether the addition of Ki67, on its own or as integrated to ER, PR and HER2, to genomic 
signatures and vice-versa may increase the prognostic performance in terms of breast cancer 
specific survival in early breast cancer (Paper III).  
 
-How survival after diagnosis of locally and loco-regionally recurrent breast cancer has 
evolved over three decades. Age-related trends in survival were also explored (Paper IV).  
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PATIENTS AND METHODS 
 
3.1 DATA SOURCE 
 
Since 1958 cancer registration is statutory in Sweden and all incident tumours must be 
reported to the Swedish Cancer Registry, whose rate of completeness is over 96%. 279 The 
National Cancer Registry was founded with the aim to provide a database, which may allow 
mapping the occurrence of cancer, monitoring changes in incidence, survival and mortality, 
facilitating clinical and epidemiological research as well as international comparisons. 280 
National cancer registration is based on data collected regionally through six Regional Cancer 
Centers. The Stockholm Breast Cancer Registry (SBCR) was established in 1976. All new 
cases of breast cancer in Stockholm County have been registered since then and the registry is 
continuously updated with the clinical follow-up and treatment of each patient. The vital 
status is instantly updated by cross-linking to the national registry. The Regional Cancer 
Centers host 28-quality registers, which are decentralised registers administered via a 
common platform, INCA (Information Network for Cancer Care) that is jointly maintained by 
the Regional Cancer Centers and replaced the regional registries in 2007. SBCR has 99% 
completeness for women 75 years or younger at breast cancer diagnosis. 281,282 The quality 
registries are often used for population-based epidemiologic studies.   
Each individual in Sweden is provided with a personal Swedish identification number, a 
unique twelve-digit number instituted in 1947 and assigned to all individuals at birth or when 
migrating to Sweden. Data from the population and health registers in Sweden are linked by 
the Swedish identification number that was used for our studies in order to identify patients 
within the SBCR. 
For all projects included in this thesis, registry data collection and analysis was approved by 
the Ethics Committee at Karolinska Institutet. 
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3.2 STUDY POPULATION 
 
Paper I 
The study cohort consisted of patients diagnosed with metastatic breast cancer (MBC) 
between January 1, 1998 and December 31, 2009 and retrospectively identified within the 
SBCR. Among those, 210 patients who had a histologic/cytologic confirmation of relapse and 
for whom Ki67 from the first loco-regional or distant recurrence (mKi67) was available were 
selected for the analysis. Information on mKi67 was manually retrieved from the database of 
the Department of Pathology at Karolinska University Hospital. Besides the absence of Ki67 
performed on first metastasis, other exclusion criteria were: diagnosis of a second invasive 
primary tumour; previous breast cancer diagnosed within five years; and bilateral 
synchronous breast cancer. All patients were diagnosed and treated for MBC at Karolinska 
University Hospital (Stockholm, Sweden). Patient demographics as well as clinical and 
pathological disease characteristics were extracted from the registry or manually collected 
from hospital records. In addition to mKi67, Ki67 was analysed in 131 primary tumours 
(pKi67). When available, pKi67 was obtained from the surgical specimen. In 43 patients who 
received neo-adjuvant treatment, pKi67 was taken from pre-treatment core-biopsies, while 
pKi67 analysed in tissue micro-arrays (TMAs) for the purpose of another study, the Merck 
study, was used in 29 cases. Merck study is a nested case-control study that aims to explore 
genomic drivers for metastatic dissemination of breast cancer (more details are provided 
below).  
 
Paper II 
The 220 patients included in this study were diagnosed and treated for primary breast tumour 
and distant recurrence at Karolinska University Hospital between January 1997 and 
September 2006 and identified within the Merck study. This study is a larger nested-case 
control study (controls are non-systemically relapsed tumours in the period 1997-2006 
matched to the cases by adjuvant therapy, age and calendar period at diagnosis) based on 
SBCR and comprises of 768 female study subjects (621 individuals including two with 
bilateral breast cancer) aged 75 or younger and diagnosed with primary breast cancer in the 
years 1997-2005. Fresh frozen primary tumour tissue was available in all patients for RNA 
isolation. Most cases had three controls each (88.4%); 15 cases (7.9%) had four controls and 7 
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cases (3.7%) had two controls. All patients were diagnosed with primary tumour between 
January 1997 and December 2005. Tumour stage IV at the time of initial diagnosis was a pre-
defined exclusion criterion. For the purpose of the analysis in Paper II, only the 220 patients 
with relapse of their cancer were selected. Clinical and pathological tumour characteristics as 
well as treatment information were collected using patient charts and pathology reports. As 
the cohort was comprised of only breast cancers that subsequently metastasized, clinically 
high-risk tumours (axillary lymph node positive, ER-negative, HER2-positive, grade 3, high 
proliferation) were more frequently represented compared with a typical early breast cancer 
population.  
 
Paper III 
The Merck study was also used as “cohort 1” in study III but the nested case-control design 
was not used here either. Overall, 621 individual patients were taken regardless of relapse 
occurrence and breast cancer specific survival (BCSS) was analysed from the time of primary 
tumour diagnosis.  The final cohort resulted in 379 subjects after exclusion of bilateral 
tumours as well as all cases in which one or more among ER, PR, HER2 or Ki67 status was 
missing. Cohort 2, referred as to the “Uppsala cohort”, consists of 484 subjects with 
systemically treated or untreated primary cancer in the Uppsala County, Sweden between 
1987-1989. Quality controlled RNA gene expression profiles were available in 253 subjects. 
After exclusion of missing gene expression profiles and unclassified tumours, 209 subjects 
were available for the analysis in cohort 2. Clinical and pathological disease information as 
well as patient follow-up was extracted from the SBCR and the Swedish National Board of 
Health and Welfare for cohort 1 and 2, respectively.  
 
Paper IV 
For the purpose of the study IV, 3898 women aged 18-75 and diagnosed with invasive loco-
regional failure (LRF) of breast cancer between January 1, 1980 and December 31, 2016 were 
identified within the SBCR. Only histologically verified invasive LRFs with no evidence of 
previous or simultaneous (within 60 days after LRF occurrence) distant metastasis were 
included. Moreover, since a quality control of SBCR included years until 2014, women 
diagnosed with a later relapse were excluded. Using these criteria, 2698 patients were selected 
for the analysis. LRFs referred to either isolated local recurrences or loco-regional 
   39 
recurrences. Data on demographics and primary tumour were obtained from the SBCR while 
information about treatment after relapse was manually retrieved from hospital records. Three 
cohorts according to the years of LRF diagnosis were derived as follows: 1980-1989; 1990-
1999; 2000-1014. Clinical follow-up and vital status were updated as of December 31,2014. 
Patients were also separated into two subgroups based on the age at relapse (≤60 years; >60 
years) and survival analysed accordingly.  
 
3.3  METHODS 
 
3.3.1 IMMUNOHISTOCHEMISTRY 
 
ER and PR 
Evaluation of the expression of ER and PR was centralized and performed at Karolinska 
Hospital laboratory using monoclonal antibody based biochemical methods (with cut-off 
≥0.05 fmol/μg DNA as positive) or by IHC/Immunocytochemistry (ICC) (with cut-off ≥10% 
as positive).23 IHC/ICC method was introduced in Sweden in 2001 and definitely replaced the 
biochemical assay in 2003. The ER and PR value that was chosen for the purpose of this 
study when results from several methods in the same patient were present, was selected in 
accordance with the following priority order: 1) IHC; 2) ICC; 3) biochemical assay.  
In paper III cohort 2, ER and PR were determined by the ligand-binding assay using the same 
cut-off as the one used at the Karolinska laboratory.  
Biochemical method and IHC/ICC provide similar prognostic and predictive information 283,284 
and the ≥0.05 fmol/μg cut-off for the ligand-binding assay has been demonstrated to be 
analogous to the ≥10% IHC cut-point. 24  
HER2 
For the paper II and III (cohort 1), HER2 was assessed in TMA sections using Chromogenic 
in situ Hybridization (CISH), in the same tumour sample used for RNA isolation.  CISH test 
was performed at University of Tampere, Finland and more comprehensive assay description 
is provided by Tanner et al. 285 For the scoring, unaltered gene copy number by CISH was 
defined as one to five signals per nucleus. Low-level amplification was defined as six to ten 
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signals per nucleus in >50% of cancer cells, while HER2 was considered as amplified when a 
large copy cluster in >50% of scored cells or >10 gene copies was detected. 285 
CISH is a reproducible validated methodology for HER2 testing and a viable alternative to 
fluorescence in situ hybridization (FISH) and IHC. A good agreement between CISH and 
FISH has been demonstrated by Tanner and coll. (kappa coefficient 0.81, 95% confidence 
intervals 0.69-0.92) 285 as well as other independent laboratories. 286,287 A good concordance 
between CISH and IHC has also been shown. 285,287  
In paper III cohort 2, HER2 was assessed on whole sections using the HER2/neu antibody 
(CB11, 1:300, NovoCastra Laboratories Ltd.)  
Ki67 
Ki67 is routinely analysed in primary and metastatic tumour tissue from patients with breast 
cancer at Karolinska University Hospital since the early 1990. When applying national 
guidelines, highly reproducible results are obtained in Ki67 assessment between Swedish 
pathology departments. 288 
 
In Paper I, mKi67 was analyzed both as a continuous and categorical variable dichotomized 
according to 20% cut-off (low ≤20%; >20% high), in agreement with local 23 as well as 
international guidelines. 289 Overall, mKi67 was analysed in 35 core-biopsies and 172 fine-
needle aspiration (FNAC) samples (biopsy source was unknown in 3 cases). FNAC and core-
biopsy are established methods for the diagnosis of primary and metastatic tumour lesions. 
290,253 A previous analysis from our group revealed low concordance of biomarkers between 
IHC and ICC, especially for Ki67, and suggested that specific cut-points should be separately 
defined for ICC. 291 Scoring variability between different methods has been ascribed to 
heterogeneity in Ki67 staining due to the presence of two biological patterns of proliferative 
activity, the tumour invasive edge and hot-spots. 253,292 Indeed, unlike core biopsy the main 
technical limitation of FNAC is the inability to accurately evaluate the abovementioned 
proliferation patterns. Furthermore, site of biopsy is an acknowledgeable source of 
heterogeneity, especially in bone biopsies, in which decalcification causes reduction in IHC 
biomarker staining. 293-295 Bone was the principal site of metastasis biopsy (28%) in paper I.  
 
Moreover, pKi67 was analyzed in 59 whole-section surgical specimens, 43 pre-surgical core-
biopsies and 29 TMA samples. Blocks for the analysis of TMA sections were initially 
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constructed at Karolinska Institutet and scored by a breast 
pathologist at Central Manchester University Hospitals NHS 
Foundation Trust, Manchester, United Kingdom for the 
purpose of the Merck study. Mib-1 antibody (1:100 diluition, 
Dako) was used for Ki67 staining. For each tumour, two 
blocks were obtained and each block was given two scores. 
Overall, 4 scores for each tumour were available.  Ki67 
scoring is presented in Table 2. The highest of the 4 scores was 
chosen and dichotomization performed as follows: low Ki67 
score ≤4; high Ki67 score >5. In 20 cases pKi67 was available both in surgical samples and in 
TMAs with an 80% concordance rate of dichotomized Ki67 between the two methods.   
Paper II and III For the purpose of these papers, Ki67 from primary tumour as assessed on 
TMAs within Merck study was also used. While in paper II the same algorithm for 
dichotomization as that used in study I was followed, in paper III 16% median cut-off was 
chosen (and applied also to cohort 2) and dichotomization performed as follows: low Ki67 
score ≤3; high Ki67 score >3. 
ER, PR, HER2 and Ki67 were used for deriving IHC-based subtypes in paper II and III.  
 
3.3.2 GENE EXPRESSION PROFILING 
 
In the Merck study, surgical specimens were divided in two parts with half being used for ER, 
PR, HER2, Ki67 and grade determination and half fresh frozen for gene expression profiling. 
RNA extraction from frozen tumours was performed using the Qiagen RNeasy Mini Kit 
(Qiagen, Germany). Hybridization of tumour samples was done using the HRSTA-2.0 custom 
human Affymetrix array, whose details can be found at NCBI Gene Expression Omnibus 
(GEO) with accession number GPL10379. Array data can be retrieved using GSE48091 as 
NCBI GEO identifier.  For the purpose of paper II and III, the tumours were profiled using the 
aroma.affymetrix package of the open source R software.  
In paper II, research versions of the commercially available PAM50 Prosigna, 21-gene 
Oncotype DX RS and 70-gene Mammaprint genomic signatures were analysed. Since more 
aggressive tumours were overrepresented in this cohort, a normalisation using the whole 
nested case-control population was carried out.  
Table 2. Ki67 scoring system in 
TMA sections 
Score Mib-1
1 0-1%
2 2-10%
3 11-15%
4 16-20%
5 21-30%
6 31-50%
7 51-100%
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For the purpose of paper III, research versions of GGI, MammaPrint, cell–cycle score (CCS), 
Oncotype DX RS and Prosigna were applied to cohort 1 and 2. Accession number for array of 
cohort 2 is available at NBCI GEO with reference GSE3494. CCS was obtained from 
METABRIC dataset in order to derive cut-offs for cell cycle activity. 296 In total, 463 cell 
cycle relevant genes were derived from 3 cohorts 296-298 and applied to 1992 cancers within the 
METABRIC dataset. A continuous score was obtained by adding all the expression values of 
these genes from each tumour. The score was then divided by tertiles (33% and 66%) in order 
to classify the tumours in low, intermediate, and high cell cycle activity. A continuous score 
was obtained in the same manner in cohort 1 and scaled to match the METABRIC score 
before applying the tertiles.  
 
3.4   STATISTICAL ANALYSIS 
 
Survival analysis is a time-to-event (or survival probability) analysis used to study the time 
to occurrence of some event of interest (or time to failure). The event of interest in our cancer 
population was death, whereas paper IV used also time to disease progression as an end-point. 
Survival was measured at the last follow-up date and analysis was right-censored. In our 
studies, median survival, that is time beyond which 50% of subjects in the population are 
expected to survive, was employed as the summary variable.  
The population of interest in paper I and II was composed of women diagnosed with MBC. 
We chose post-relapse OS, defined as the time interval between first distant relapse 
occurrence and death irrespective of the cause, as the primary end-point assuming that the 
majority of deaths were related to breast cancer. In paper IV, post-relapse event-free survival 
(EFS) was calculated as the time between LRF occurrence and disease progression, consisting 
in a second loco-regional failure, distant relapse or death. Estimates of survival were from 
Kaplan-Meier method, a non – parametric statistical test used when survival is on a 
continuous scale and particularly useful in presence of right censoring. Comparisons between 
groups were made by the log-rank non-parametric test. 299 Unadjusted Cox regression analyses 
were fitted for hazard ratio (HR) and confidence intervals (CI) estimation. In order to test for 
the effect modification caused by potential confounding factors, multivariate Cox proportional 
regression models were implemented. The Cox model is a semi-parametric model that allows 
for comparison of effect of different exposures on a time to event outcome. 300 The clinical 
variables selected for multivariate model adjustment were tumour size, hormone receptor 
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status, Ki67 and grade of the primary tumour, axillary lymph node status, age at relapse, 
primary tumour surgery (paper IV), recurrence free interval (RFI), site of first metastasis 
(visceral vs. non-visceral), treatments at the initial diagnosis, first line treatment for the 
advanced disease (paper II).  
Net survival is the proportion of patient that survives in the hypothetical scenario where the 
cancer of interest is the only possible cause of death. In paper IV, relative survival was used to 
estimate net survival. Relative survival is the ratio of the observed survivors in the study 
cohort to the expected survivors in the general population, which is comparable for age, sex 
and calendar period to the study cohort but free of the cancer of interest. The estimate of 
relative survival is the excess mortality ratio (EMR), which measures the mortality the 
patients experience in excess of what would be expected in absence of the cancer of interest. 
301 Survival estimates in the general population were extrapolated from The Human Mortality 
Database that contains population life tables from 37 countries. 302 Relative survival has the 
advantage of not requiring cause-specific mortality thus circumventing limitations related to 
incorrect reporting or lack of death certificates. A Poisson regression model was fitted for 
estimating breast cancer EMRs for clinically relevant prognostic factors. 303  
Likelihood ratio statistics In paper II and III, the likelihood ratio (LR) statistics was applied 
to test the goodness-of-fit of a model that implies estimating whether an expanded model 
provides improved fits as compared to a reduced one. 304 In detail, paper II studied the 
additional prognostic contribution in terms of post-relapse OS prediction of the PAM50 ROR 
weighted for an 11-gene proliferation index (ROR-P) when added to a clinical model alone or 
in presence of the other explored tumour prognosticators. Breast cancer specific survival 
(BCSS) was the clinical end-point for paper III, which analyzed a cohort of primary breast 
cancers. Here, the LR statistics (LR-χ2) was used to study whether genomic signatures carry 
additional prognostic significance when added on the top of Ki67/IHC-based subtypes and 
whether Ki67 alone or integrated into IHC-subtypes may confer more prognostic information 
when added to these signatures. A concordance index (c-index), which measures the 
predictive discrimination (probability of concordance) between predicted and observed 
outcome between variables or models, was also applied in paper III. 304  
 
Furthermore, associations between baseline characteristics and variables of interest were 
explored by using the Pearson’s chi-square test in all the papers (the Mann-Whitney test was 
also used in Paper III) while the k-coefficient was estimated to measure to degree of 
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agreement between IHC and genomic prognosticators in paper II. 305 In paper I, the 
McNemar’s test, a test that investigates whether there is marginal homogeneity between 
paired data, was used to explore changes in dichotomized pKi67 and mKi67 in matched 
primary tumours and metastasis. 306  
 
Two-sided tests were used with 5% significance level. All analyses were performed and 
results reported in accordance with the “REMARK” guidelines. 78 
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RESULTS 
 
Paper I – Prognostic role of Ki67 assessed in metastatic tissue of patients with advanced 
breast cancer. 
 
In this study, the prognostic role of Ki67 from metastasis biopsies as well as the change in 
Ki67 expression rate in first relapse compared with corresponding primary tumour and its 
clinical implications has been determined. 
Overall, 125 (59.5%) and 85 (40.5%) patients had low and high mKi67, respectively. As the 
cohort was exclusively composed of MBCs, primary tumours carrying more aggressive 
features were overrepresented in the study cohort as compared with the general breast cancer 
population. In detail, there was an excess of larger (>2 cm) primary tumours (60%) with 
axillary lymph nodes metastatic involvement (66%) as well as ER-negative (36%) and 
undifferentiated (44%) primary cancers. However, this metastatic breast cancer cohort was 
fairly representative of the overall metastatic breast cancer cohort from the SBCR in terms of 
baseline characteristics as well as post-relapse OS (median OS 15 months). 14 Interestingly, 
mKi67 rate was highly associated with primary tumour grade (Pearson’s chi-square p 0.01) 
and 73% of patients with low mKi67 had RFI ≥24 months. The most frequent site of biopsy 
was bone (28%) and liver (23%). In 15 patients mKi67 was analysed in at least two relapse 
sites at time of first recurrence. In 14 cases FNAC was the method used to assess Ki67 in 
multiple first relapses from the same subject with 
100% and 50% agreement between two or more 
first relapses when classifying mKi67 as low or 
high, respectively.  
A total number of 186 deaths were registered, 
109 in the low-mKi67 and 77 in the high-mKi67 
group. Low mKi67 levels were significantly 
associated with longer median post-relapse OS 
(25 vs. 17 months; HR 0.69, 95% CI 0.51-0.92; 
p 0.01). Conversely, pKi67 was not 
significantly prognostic of survival after relapse 
Figure 7. Kaplan-Meier estimates of OS grouped 
by levels of Ki67 on primary tumour  
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(Figure 7). When a regression Cox model stratified by RFI was adjusted for clinical 
prognostic variables statistically significant in univariate models, namely axillary lymph node 
status, RFI, primary tumour ER and site of metastasis, mKi67 did not retain an independent 
association with OS (HR 0.85, 95% CI 0.62-1.16, p 0.30). Absence of metastasis in the 
axillary lymph nodes at primary diagnosis (p 0.005) and non-visceral metastasis (p 0.01) were 
independently prognostic of longer post-relapse OS. However, in a bivariate Cox regression 
model mKi67 significantly correlated with OS regardless of pKi67 (HR 0.56, 95% CI 0.38-
0.81, p 0.002). The prognostic value of Ki67 was also explored in subgroups of tumours 
defined by axillary lymph node status and ER (Table 3). Low-mKi67 was associated with 
longer OS in the group of negative lymph node status (p 0.016) whereas no statistically 
significant association emerged from the analysis of the positive axillary lymph node group (p 
0.24) as well as in ER-positive (p 0.37) and negative (p 0.13) subgroups.  
N N of events Median (months) HR (95% CI) P HR (95% CI) P
Axillary lymph node negative status of primary tumor 70 57 25 0.72 (0.53-0.97) 0,029
mKi67 low (≤20%) 43 35 46 0.51 (0.29-0.89) 0,016
mKi67 high (>20%)a 27 22 19
Axillary lymph node positive status of primary tumorb 139 128 18
mKi67 low (≤20%) 81 73 20 0.81 (0.57-1.16) 0,243
mKi67 high (>20%)a 58 55 16
ER  positve status of primary tumor 127 113 24 0.78 (0.58-1.06) 0,108
mKi67 low (≤20%) 83 74 28 0.84 (0.57-1.24) 0,374
mKi67 high (>20%)a 44 39 21
ER  negative status of primary tumorb 76 67 14
mKi67 low (≤20%) 38 32 15 0.69 (0.43-1.13) 0,132
mKi67 high (>20%)a 38 35 11
bReference for the overall survival comparison between low and high metastatic Ki67in axilary lymph node positive vs. negative and in ER positive 
vs. negative tumor subgroups.
OS between subgroupsOS within subgroup
Abbreviations: OS, overall survival; N, number of patients; HR, hazard ratio; 95% CI, 95% confidence intervals; P, p-value; mKi67, metastatic Ki67;  
ER, estrogen receptor.
aReference for the overall survival comparison between low and high metastatic Ki67 within the subgroup.
 
 
When the analysis was restricted to mKi67 assessed in FNAC, thus accounting for a potential 
source of heterogeneity related to different techniques, the results were substantially 
unchanged.  
Moreover, the prognostic role of the continuous Ki67 was explored showing that increasing 
levels of mKi67 correlated with increasing death rate at 2 years (HR 1.09, 95% CI 1.04-1.14, 
p 0.001).  
Table 3. Cox regression analysis for OS depending on subgroups defined by axillary lymph node status and 
ER status at primary diagnosis (Modified from Falato C et al., Breast Cancer Res Treat 2014) 
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Dichotomized Ki67 was available in 131 primary 
tumours and changed in 54 cases (41%) (p 0.02 
by McNemar’s test), from low in the primary 
tumour to high in the metastasis in 18 (14%) and 
from high to low in 36% (28%) cases. 
Continuous Ki67 was available in 67 matched 
primary tumours and metastases (Figure 8). 
Although the difference was not statistically 
significant (p 0.8 by t-test for paired samples), 
the mean Ki67 values tended to be lower in 
metastasis compared to primary tumours (23 vs. 
32).  
Furthermore, the prognostic value of the change in dichotomized Ki67 was addressed. 
Compared to the stable Ki67 category, the change in Ki67 from high to low levels was 
associated to a better post-relapse OS (HR 0.48, 95% CI 0.31-0.76, p 0.002) while no 
difference was seen when Ki67 varied from low in primary tumour to high in correspondent 
metastasis (HR 1.06, 95% CI 0.62-1.80, p 0.83). When the stable group was separated in 
stable low or stable high, the change of Ki67 levels from high to low was still associated with 
better survival (p 0.005), suggesting that the decrease in Ki67 rather than Ki67 rate in 
metastasis may be prognostically relevant (Figure 9). 
 
Figure 8. Continuous Ki67 in primary 
tumour and metastasis 
Figure 9. Survival in relation to Ki67 in primary tumour and metastasis 
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In a further exploration, the association between the variation in Ki67 and clinicopathological 
factors, including neo/adjuvant treatments, was investigated. Only RFI >24 months 
significantly correlated with variation in proliferation rate with Ki67 changing to low in 24 
(59%) out of 41 patients with initially high pKi67.  
 
Paper II – Post-relapse prognosis according to immunohistochemical subtypes and 
genomic signatures from primary tumour in patients diagnosed with metastatic breast 
cancer. 
 
This study explored the prognostic value in terms of post-relapse OS of breast cancer 
subtypes and genomic signatures from primary tumour, beyond classical clinical and 
pathological prognostic factors.  
Table 4 summarizes tumour classification according 
to IHC-based subtypes and genomic profiles. 
Notably, since the cohort is composed of advanced 
breast cancers 85% and 67% of the tumours in the 
overall population were classified as high-risk and 
poor prognosis based upon the 21-gene RS and the 
70-gene classifiers, respectively. RS categorized ER-
positive tumours as high-risk in the 79% of the cases. 
As a prove of concept, all the tested classifiers were 
explored for their association with survival from 
primary diagnosis and the results were in line with 
the main findings of the study. More specifically, a 
statistically significant association between IHC-as 
well as PAM50-based intrinsic subtypes and overall 
survival from primary tumour was shown (p 0.007 
and p 0.003 by log-rank test, respectively). Moreover, 
ROR-S and the 70-gene profile were prognostic of 
overall survival (p < 0.001 and p 0.007 by log-rank test, respectively) while no statistically 
significant association emerged between RS and survival from diagnosis of primary tumour (p 
0.179). 
Table 4. Classification based on IHC 
biomarkers and genomic profiles 
Overall 
cohort ER positive 
Variable N (%) N (%)
IHC classifier _
luminal A 49 (27)
luminal B 45 (24)
HER2 positive 67 (36)
TNBC 23 (13)
Total 184 (100)
PAM50 _
luminal A 41 (22)
luminal B 44 (24)
HER2 enriched 49 (26)
Basal-like 41 (22)
Normal breast-like 12 (6)
Total 187 (100)
ROR-S _
low 34 (18)
medium 67 (36)
high 86 (46)
Total 187 (100)
Recurrence Score
low 11 (6) 11 (9)
intermediate 17 (9) 15 (12)
high 159 (85) 98 (79)
Total 187 (100) 124 (100)
70 gene signature
good 62 (33) 54 (44)
poor 125 (67) 70 (56)
Total 187 (100) 124 (100)
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Intrinsic subtypes as assessed by IHC-biomarkers and PAM50 were assessed. Only a 
moderate degree of agreement between the two classifiers was present (kappa score = 0.51), 
as Figure 10 shows. In fact, PAM50 molecular subtypes are represented in each IHC 
subgroup and vice-versa with highest discordance in the Basal-like group. In this study 
cohort, Luminal B category by IHC was defined as ER-positive and/or PR-positive, HER2-
negative and Ki67 ≥20%, while all cancers overexpressing HER2 were categorized as HER2-
positive irrespective of hormone receptor status.  
  
 
 
 
First, IHC and PAM50 subtypes were found significantly associated with post-relapse OS (p 
0.05 and p 0.03, respectively). Unlike primary breast cancer, no significantly different 
survival was described in the comparison of Luminal B with Luminal A cancers (p 0.99 and p 
0.45 by IHC and PAM50). Neither IHC-subtypes (p 0.64) nor PAM50 (p 0.58) retained an 
independent prognostic performance when a Cox multivariate model was implemented to 
Figure 10. Intrinsic subtype distribution within IHC subtypes and vice-versa 
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account for the effect of routinely employed clinical and pathological factors. As an 
exploratory analysis, HER2-positive tumours were further separated in hormone receptor-
positive/HER2-positive and hormone receptor-negative/HER2-positive and post-relapse OS 
estimated by the Kaplan-Meier method. Notably, the hormone receptor-positive/HER2-
positive group was associated with a significantly shorter survival (p 0.02) in comparison with 
Luminal and hormone receptor-negative/HER2-positive tumours. The ability of Ki67 at 15% 
cut-off as well as continuous Ki67 in separating Luminal tumours was also tested with 
consistent results in terms of survival prediction. 
Furthermore, a good agreement was seen between PAM50-based ROR (ROR-S), RS and the 
70-gene good and poor prognosis categories, although more tumours were classified as high 
risk according to RS. These signatures were tested for association with survival both in the 
overall cohort and in ER-positive tumours. A significant correlation with longer post-relapse 
OS was described only for low and medium ROR-S categories and 70-gene poor and good 
categories in the overall but not in ER-positive group.  RS was not prognostic and, thus, not 
further investigated in the multivariable model. ROS-S (low-risk HR 0.59, 95% CIs 0.34-
1.01; medium-risk HR 0.58, 95% CIs 0.37-0.91; p 0.04) but not the 70-gene classifier (good 
prognosis category HR 0.90, 95% CIs 0.57-1.40; p 0.64) was independently associated with 
survival in a Cox regression model adjusted for significant clinical and pathological variables. 
However, the association between low-risk ROS-S and better survival was borderline, likely 
due to the low number of events.  Results were unchanged when grade was removed from the 
model.  
An 11-proliferation gene signature derived from PAM50 was also tested and a significant 
correlation with post-relapse OS was seen in univariate (HR 1.62, 95 CIs 1.09-2.41, p 0.02) as 
well as multivariable Cox regression models (HR 1.74, 95% CIs 1.09-2.78, p 0.02).  
Additionally, ROR-S weighted for the proliferation score (ROR-P) was investigated. ROR-P 
provided additional prognostic information when added to a clinical model including primary 
tumour size and grade, RFI and first systemic relapse site alone (p < 0.001) or in presence of 
the RS (p < 0.001), 70-gene signature (p < 0.001), ROR-S (p 0.01) and IHC subtypes (p 0.01). 
Finally, survival in subgroups of patients identified according to the first line treatment for 
metastatic disease was tested. Trastuzumab was administered in 48 out of 67 HER2-positive 
tumours. Low-risk ROR-S was associated with a clinically relevant and statistically 
significant longer survival in ER-positive tumours treated with endocrine treatment (p 0.002) 
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but not in those treated with chemotherapy (p 0.097). Moreover, PAM50 better identified 
Luminal A tumours that could benefit from first line endocrine therapy in comparison with 
IHC, although the difference in survival between Luminal A and B did not reach the 
significance level in any of the subgroups (endocrine treated and chemotherapy treated 
patients). However, the analysis was purely explorative and not intended to provide treatment 
indications.  
 
Paper III – Evaluation of the additional prognostic role in early breast cancer of 
genomic signatures and immunohistochemical subtypes when combined to each other.  
 
This study investigated whether Ki67 alone or incorporated into IHC subtypes as combined 
with genomic signatures, and vice-versa, might provide more prognostic information than 
each classifier alone in early breast cancer setting.  
For both cohort 1 and cohort 2, all analyses were performed in the whole patient population as 
well as in subgroups defined as follows: ER-positive/lymph node negative, ER-
positive/lymph node positive, ER-negative. Cohort 1 was derived from a nested-case control 
study in which cases developed a relapse and controls did not during the same time frame 
(Merck study, see Methods above for details).  This led to an overrepresentation of tumours 
with more aggressive features, in particular more histologic grade 3 and highly proliferative 
tumours with larger size and lymph node metastases at primary diagnosis in patients with 
younger age, in cohort 1 in comparison with cohort 2. Additionally, in cohort 2 fewer patients 
received adjuvant systemic treatment and 65% of patients with ER-positive tumours were not 
treated with endocrine therapy.  
In both cohorts, the rate of discordance between Ki67 at a 16% cut-point and the other 
genomic classifiers was in the range between 14% and 22%, as expected from previous 
studies (Table 5).  
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Cross-table of concordance between Ki67 immunohistochemical staining and gene expression signature classifications in the Cohort 1 
and 2
Number of patients grouped by Ki67 status in the Cohort 1 and 2
Cohort 1 (n=379) Cohort 2 (n=209)
Characteristics
Ki67 < 16 
(n=184)
Ki67 ≥ 16 
(n=195)
Ki67 ≥ 16 
(n=69) nC nD
n (%) n (%) n (%)
nC nD Ki67 < 16 (n=140)
n (%) n (%)
Gene expression signatures
n (%) n (%) n (%)
GGI
Grade 1 120 (65) 14 (7) 301 (79) 168 (80) 41 (20) Grade 3 64 (35) 181 (93) 21 (15)78 (21) 
119 (85) 20 (29)
49 (71)
Good 142 (77) 32 (16) 305 (80) 
70-Gene
163 (78) 46 (22)Poor 42 (23) 163 (84) 38 (27)74 (19) 
102 (73) 8 (12)
61 (88)
Low 71 (39) 5 (3) 
296 (78) 
Recurrence score
43 (21)Intermediate
8 (12)
5 (7)
56 (81)High 78 (42) 180 (92) 35 (25)
35 (19) 10 (5) 35 (25)83 (22) 
70 (50)
166 (79) 
Low 70 (38) 3 (1) 
326 (86) 
Cell Cycle score
22 (11)Intermediate 64 (35) 16 (8) 26 (19)53 (14) 
103 (74) 11 (16)
22 (32)
36 (52)High 50 (27) 176 (91) 11 (8)
187 (89) 
Luminal A 111 (60) 15 (7) 
307 (81) 
PAM50
HER2-enriched 12 (6) 41 (21) 18 (13) 150 (72) 
54 (28) 27 (19)
72 (19) 
54 (39) 3 (4)
18 (27)
GGI = Genomic grade index, nC = Number of concordant cases, nD = Number of discordant cases
Numbers in red = Cases in which Ki67 and gene expression signatures are not in agreement.
15 (22)
Normal-Like 23 (12) 7 (4) 33 (24) 3 (4)
Basal-Like 14 (8) 78 (40) 8 (6)
59 (28) 30 (43)
Luminal B 24 (13) 
 
 
Among 379 patients included in the analysis in cohort 1, 104, 167, and 103 were categorized 
in the group of ER-positive/lymph node negative, ER-positive/lymph node positive and ER-
negative tumours, respectively. The 21-gene RS and PAM50, but not the other genomic 
profiles, provided statistically significant additional prognostic information on top of Ki67 
(RS: LR-χ2 test p 0.001; PAM50: LR-χ2 test p < 0.001) and IHC subtypes (RS: LR-χ2 test p 
0.001; PAM50: LR-χ2 test p0.020) in the overall cohort (Figure 11). None of the signatures 
conferred additional prognostic value in ER-positive/lymph node negative, while all were 
associated to an increased prognostic performance when added to Ki67 and IHC subtypes in 
ER-positive/lymph node positive group, suggesting a superior prognostic ability for gene 
signatures as compared to the IHC biomarkers in this specific subset (Figure 11). Gene 
expression signatures, which are notably driven by proliferation genes, did not show any extra 
prognostic capacity in ER-negative tumours, except for the 21-gene RS for which a trend 
towards an improved prognostication was demonstrated (LR-χ2 test p 0.058). Furthermore, the 
additional prognostic performance of Ki67/IHC subtype when added to genomic profiles was 
assessed in the same subgroups. Ki67 did not add any prognostic information in any patient 
Table 5. Concordance between Ki67 subgroups and gene expression signature classification (Modified from 
Lundberg A et al., CCR 2017) 
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subgroup while IHC subtypes were associated to an improved prognostication when added to 
all signatures in the overall and ER-negative subset, except for PAM50 that showed more 
robust prognostic capacity in comparison with IHC classifiers (Figure 11). Analysis of the c-
index led to consistent results in all subgroups. 
 
 
Cohort 2 included 209 patients. Of these, 115 had ER-positive/lymph node negative, 65 had 
ER-positive/lymph node positive and 24 had ER-negative tumours. In general, the results 
were consistent with those from cohort 1 despite the smaller sample size of cohort 2, 
particularly in ER-positive/lymph node positive and ER-negative subgroup. An exception was 
that all gene expression signatures when combined to Ki67 and IHC subtypes performed 
better here than in cohort 1 in the overall population but not in the ER-positive/lymph node 
positive group, likely due to the lower sample size. Probably due to the same reason, IHC did 
not provide additional prognostic information beyond PAM50. Strikingly, both Ki67 and IHC 
Figure 11. Representation of the additional prognostic information deriving from adding A) genomic 
signatures to Ki67/IHC-subtypes and B) Ki67/IHC subtypes to genomic signature.(Modified from Lundberg A 
et al., CCR 2017) 
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subtype were significantly prognostic in ER-negative tumours (p < 0.001) on the top of the 
21-gene signature.  
 
Paper IV – Prognosis after loco-regional failure of breast cancer: 34 years longitudinal 
data from the Stockholm-Gotland cancer registry 
 
The study investigated survival in patients diagnosed with LRF in Stockholm County and 
explored potential survival trends over the past three decades. 
Overall, 1922 and 996 patients received a diagnosis of isolated local relapse and loco-regional 
relapse, respectively. Median follow-up time was 13 years. More local and less loco-regional 
relapses were diagnosed over time, likely as a result of the wider use of breast conserving 
surgery and the better loco-regional control obtained with modern radiotherapy in the most 
recent decades. In addition, a trend towards smaller primary tumours, lower rate of axillary 
lymph node metastasis but also increasing use of neoadjuvant/adjuvant chemotherapy was 
shown over time (Mantel-Haentzel test for trend p < 0.001). No trend over time was 
demonstrated for ER status (Mantel-Haentzel test for trend p 0.75).  
Information on relapse treatment was available only for the last cohort. Surgery was 
performed in 76% and 65% of the isolated local and regional recurrences diagnosed from 
2000 and onward. Radiotherapy and chemotherapy were more frequently administered after a 
loco-regional relapse (20% and 28% vs. 57% and 51% in local relapse group) while the 
percentage of endocrine treated patients after relapse was similar between the groups (54% vs. 
58% in local and loco-regional relapse, respectively).  
Overall, 1032 (54%) out of 1922 diagnosed with a local relapse experienced disease 
progression, and of those 12% recurred loco-regionally, 51% systemically while 37% died 
without a second relapse. Among women diagnosed with loco-regional relapse, 11% further 
relapsed loco-regionally, 65% systemically and 24% died without documented progressive 
disease. In total 931 (48%) and 522 (67%) deaths were registered in the group of local and of 
loco-regional relapses, respectively. A significant improvement over time in post-relapse EFS 
and OS was described in both isolated local and loco-regional relapse groups.  
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Age-related trends were observed in the group of loco-regional but not in that of local 
recurrences. In fact, in locally relapsed tumours survival changed independently of age at 
recurrence (≤60 years; >60 years) while in loco-regional recurrence group a significant 
change was described for the overall cohort and for younger but not for older women. 
Moreover, in multivariate models stratified by RFI, cohort by year of relapse was associated 
with improved EFS and OS independently of other clinical prognostic factors only in the 
overall cohort and younger women within the loco-regional relapse group but not in older 
patients and in the group of isolated local recurrences (Table 6).   
Variables HR (95% CIs) P HR (95% CIs) P HR (95% CIs) P HR (95% CIs) P HR (95% CIs) P HR (95% CIs) P
Cohort  
1980-1989 1.14 (0.93-1.39) 0.19 1.31 (0.96-1.77) 0.08 1.02 (0.78-1.33) 0.88 1.35 (1.07-1.7) 0.01 1.85 (1.32-2.59) < .001 0.9 (0.65 -1.25) 0.54
1990-1999 0.94 (0.80-1.10) 0.43 1.04 (0.83-1.32) 0.71 0.82 (0.66-1.02) 0.08 1.28 (1.05-1.58) 0.02 1.59 (1.19-2.13) 0.002 1.03 (0.76-1.39) 0.86
2000-2014a 1 1 1 1 1 1
Cohort  
1980-1989 1.06 (0.86-1.31) 0.59 1.25 (0.91-1.73) 0.17 0.98 (0.75-1.31) 0.93 1.27 (1.01-1.62) 0.05 1.75 (1.23-2.48) 0.002 0.91 (0.65-1.28) 0.59
1990-1999 0.90 (0.76-1.07) 0.23 0.95 (0.73-1.23) 0.69 0.88 (0.70-1.10) 0.26 1.20 (0.97-1.49) 0.09 1.56 (1.15-2.12) 0.005 0.98 (0.72-1.34) 0.9
2000-2014a 1 1 1 1 1
areference
HR hazard ratio, CIs confidence intervals, P p- value
Event-free survival
Overall Survival
**The model is stratified for recurrence free interval adjusted for primary tumor size and axillary lymph node status at time of primary diagnosis.
*The model is stratified for recurrence free interval and adjusted for type of primary surgery, primary tumor size and estrogen receptor, axillary lymph node status at 
time of primary diagnosis, adjuvant/neoadjuvant chemotherapy, age at diagnosis of local relapse (only overall cohort analysis).
Isolated local recurrence* Loco-regional recurrence**
Overall cohort Patients ≤60 years Patients >60 years Overall cohort Patients ≤60 years Patients >60 years
 
 
Results were essentially unchanged when the analysis was restricted to women aged ≤70 
years at relapse accounting for the heterogeneity with respect to survival when older patients 
are included into the study population.  
Relative survival and EMSs were in accordance with post-relapse EFS and OS and relative 
hazard estimation. Relative survival curves are illustrated in Figure 12.  
Table 6. Multivariate analysis for post-relapse survival in patients with loco-regional failure of breast cancer 
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All the analyses were unchanged when restricted to the years 1980 through 2009.  
In an exploratory analysis, the 2000-2014 cohort was further divided in two sub-cohorts 
(2000-2005; 2006-2014) and survival was compared between these groups, aiming to further 
dissect this period that was characterized by the introduction of new compounds in breast 
cancer management (especially anti-HER2 therapies). Surprisingly, a better post-relapse EFS 
(p 0.002) and OS (p 0.03) was shown for older patients in the loco-regional relapse group but 
not for the other subgroups. Figure 13 and Figure 14 present post-relapse EFS and post-relapse 
OS curves, respectively. The improvement in survival remained significant for the older 
patients with loco-regional relapse diagnosis in Cox multivariate models adjusted for clinical 
confounding factors (EFS, p 0.003; OS, p 0.03). In the same patient subgroup, a clear trend 
towards an improved relative survival was also demonstrated (p 0.06). 
 
Figure 12. Relative survival curves according to type of loco-regional failure and age at relapse 
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Figure 13. Post-relapse event-free survival curves according to type of loco-regional failure and age 
at relapse in the cohort 2000 -2014 
Figure 14. Post-relapse overall survival curves according to type of loco-regional failure and age at 
relapse in the cohort 2000 -2014 
  58  
CONCLUSIONS 
 
A clinical useful prognostic biomarker has to show the ability to separate a population into 
clinically relevant subgroups characterized by different prognosis and must add relevant 
information to the prognostic factors already used in clinical practice. The combination of 
clinical and pathological markers with newer genomic tools has the potential to optimize the 
identification of prognostic groups compared to each of these factors alone. The reason for that 
may be ascribed to their differential biological rationale so as each factor may rather refine and 
enhance the information carried from another biomarker, instead of replacing it. Population-
based studies represent an extreme valuable tool for their ability to picture the variation of 
survival in a real scenario over decades and on a long-term follow-up. Discovering trends in 
survival may help, for example, to pinpoint those patient categories that benefited less of the 
improved therapies and to canalize research efforts towards a more personalized selection of 
the candidates to certain treatments. More specifically: 
- In paper I, Ki67 from metastasis outperformed Ki67 of the primary tumour as a 
prognostic factor of survival after relapse but its role was not independent from the 
classical and well-established prognosticators. The change in Ki67 rate during tumour 
progression revealed the existence of potential biological implications in determining 
survival in the advanced setting.  
- In paper II, ROR score from primary tumour, particularly when combined to 
proliferation genes, may act as a prognosticator of survival after recurrence beyond 
clinical prognostic determinants. It supports the utility of the combination of different 
prognosticators in routine practice and offers an alternative when the biopsy of the 
relapse is not feasible. 
- In paper III, genomic signatures demonstrated to compete well with IHC subtypes on a 
long-term prognostication in early breast cancer and that the use of several biomarkers 
may improve the ability to predict survival compared with a single biomarker. 
- In paper IV, a significant improvement of survival after local and loco-regional relapse 
has been described over three decades. An improved local control after primary 
surgery plays an important role leading to later and less extended local relapses with a 
higher chance to be radically operated. However, older women benefited less of the 
advances in breast cancer treatments, likely due to less aggressive therapeutic 
approaches. Therapy after relapse excision needs standardization to achieve further 
enhancements. 
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DISCUSSION 
 
Breast cancer is a multifaceted disease whose variegate phenotype only partially recapitulates 
the underlying biological complexity. Treatment choices in routine management principally 
rely on the clinical and pathological characteristics of the disease, although molecular 
classification currently offers information alongside that provided by clinical and pathological 
examination. 121,239 Breast cancer phenotype continuously evolves during tumour progression 
and, while methodological issues might in part explain discrepancy in biomarker expression 
between primary tumour and metastasis, the contribution of innate and treatment-induced 
genomic instability is well demonstrated. 191-194,262,263,265,269 Loss of ER and PR in metastasis as 
compared to primary tumour is associated to poorer post- relapse survival in contrast to stable 
receptor expression. The use of adjuvant endocrine therapy alone or in combination to 
chemotherapy has been significantly associated to higher proportion of tumours losing 
hormone receptors during disease progression in comparison with no adjuvant treatment. 191,192 
Indeed, it has been shown that metastases are enriched for proliferation and migration genes as 
compared to primary tumours and the pattern of genomic heterogeneity between primary 
tumour and metastasis reflects a pattern of acquired oestrogen independence. 266 The studies in 
this thesis focused on the prognostic role of proliferation in advanced breast cancer, its 
interaction with other known clinicopathological and molecular prognosticators and the 
investigation of their combination for the purpose of refined breast cancer stratification.  
Sustained proliferation is essential in cancer growth and progression. 29 Paper I provided the 
first evidence of the prognostic value of proliferation in advanced disease and revealed a 
substantial instability in proliferation rate between primary tumour and metastasis. It is not 
surprising that Ki67 did not retain an independent association with post-relapse survival when 
the effect of other prognostic variables was examined. This is in line with most studies in early 
breast cancer, especially when lymph node positive and, thus, more aggressive tumours were 
analysed. Moreover, ER-negative tumours, which are notably characterized and driven by 
higher proliferation rates, were overrepresented in this study cohort in comparison with a 
general breast cancer cohort (36%), leading to an overlap of biological and prognostic 
information. Variation in Ki67 rate during endocrine treatment and predictive ability of this 
change has been shown in prospective cohorts in the neoadjuvant setting. 247,248 In this study, a 
clear association between treatment as well as most of the explored clinical variables and 
change in Ki67 was not demonstrated. Despite that, the significantly better survival associated 
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to lower rate of Ki67 in metastasis suggest an undiscovered underlying biological rationale 
worth further explorations.  
Clinical management of metastatic breast cancer may be improved by the reassessment of 
biomarkers in the relapse tissue. Molecular subtypes vary in metastasis as compared with 
primary tumour and breast cancer subtypes in the relapse showed a prognostic value in 
advanced disease. 195,266 However, metastasis biopsy, although frequently feasible, could turn 
out in the collection of insufficient material for gene expression analysis. Paper II provided the 
evidence that ROR, as assessed in primary tumour tissue, has an independent prognostic value 
in terms of post-relapse survival and might allow tailored prognostication in advanced setting. 
This paper provided also a further evidence of the independent prognostic relevance of 
proliferation after relapse occurrence and to its ability to enhance the prognostic performance 
of ROR on the top of other clinical and molecular prognosticators.  
In line with the increasing evidence of the reciprocal contribution of IHC markers and gene 
signatures in refining breast cancer stratification and prognostication, Paper III revealed that 
the 21-gene array and PAM50 provided additional prognostic information beyond Ki67 and 
IHC subtypes on a long-term follow-up. Additionally, all the investigated signatures added 
significant information in the lymph node positive subgroup, in which the value of genomic 
signatures is notably still controversial. Ki67 alone did not outperform any gene expression 
array, most of which are driven by proliferation. However, all the IHC biomarkers together 
added significant prognostic information compared to all gene arrays except PAM50, 
confirming its strong biological basis. None of the genomic signatures provided relevant 
prognostic contribution in ER-negative tumours further indicating their limited value in this 
subgroup. The results were confirmed in a second and not comparable cohort highlighting the 
strength and generalizability of these findings.  
During the past two decades, new drugs have been introduced in breast cancer treatment. 
Whether these new compounds have led to an improved survival in the general population 
outside clinical trials has been matter of debate. In this sense, population-based studies from 
cancer registries represent an invaluable tool for survival trends explorations. We 
demonstrated a survival improvement after local and loco-regional relapse of breast cancer 
over 34 years. However, survival in locally relapsed tumours was not improved in the years 
2000-2014 compared with the years 1990-1999. Although interpreting these results is 
complicated by the increasing use of breast conserving surgery followed by radiotherapy in the 
last 20 years, these findings suggest the need of more standardized therapeutic approaches 
after relapse excision. The last two decades have been also characterized by a more extensive 
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use of adjuvant systemic therapies, which have been found to independently correlate with 
worse post-relapse survival. 14 Selection of more aggressive and resistant cell clones, with 
acquired oestrogen-independence especially in endocrine-treated tumours, could explain the 
lack of improvement in survival in the years 2000-2014 compared to the previous decade. 
Moreover, survival did not improve over time in the older population diagnosed with more 
extended relapses. Less intensive treatments due to comorbidities as well as age- related 
decreased functional reserve of multiple organs, physiological pharmacokinetic modifications, 
and use of concomitant medications might contribute to the reduced benefit from cancer 
treatments and, consequently, unchanged survival.  
The abovementioned considerations leave some unanswered questions and open future 
research perspectives. In particular: 
- Exploration of the biological grounds of the change in Ki67 during tumour progression 
and its interaction with clinical factors, particularly given treatments; 
- Prospective investigation of Ki67 prognostic and predictive value in advanced disease 
and its contribution as a component of a prognostic and predictive algorithm in 
metastatic breast cancer; 
- Identification of low-risk patients who could benefit mostly of first line endocrine 
treatment for metastatic disease (e.g. as identified by PAM50 ROR); 
- Promoting clinical trials investigating drugs in highly selected population of patients 
identified by multilevel integration of stratification biomarkers (e.g. fraction of HER2-
positive tumours with unaltered PI3KCA pathway and normal levels of PTEN within 
the HER2-enriched tumours); 
- Identification and improvement of therapeutic strategies based on the evidence of 
potential treatment-induced clonal selection and genomic modifications; 
- Canalizing research efforts with the aim to find efficacious treatment options for those 
groups of patients usually not included in clinical trials and who benefit less of the 
therapeutic advancements (e.g. older patients); 
- Standardizing treatment protocols using more tailored patient risk categorization based 
on clinical, molecular and new genomic stratification markers. 
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